REPLIGEN CORP 10-K

ITEM 9A. CONTROLS AND PROCEDURES (a) Disclosure Controls and Procedures. The Company’s management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act and as required by paragraph (b) of Rules 13a-15 or 15d-15 under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective at the reasonable assurance level. (b) Report of Management on Internal Control Over Financial Reporting. Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, the Company’s principal executive and principal financial officers and effected by the Company’s Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and includes those policies and procedures that: • pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; • provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and • provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements. Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2022. In making this assessment, management used the criteria established in Internal Control – Integrated Framework , issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO). In connection with our initiative to integrate and enhance our global information technology systems and business processes, we continued the phased implementation of a new enterprise resource planning (“ERP”) system. The Company is implementing the ERP system in phases and will continue until all current and future subsidiaries are using it. The fourth phase of implementation was completed during the first quarter of 2022. In addition, we completed the implementation of a lease accounting system, LeaseQuery, during the first quarter of 2022. As a result of these implementations, we modified certain existing internal controls over financial reporting as well as implemented new controls and procedures related to the new ERP system and LeaseQuery system as of December 31, 2022. Other than the foregoing, there have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 54 Subject to the foregoing, based on this assessment, our management concluded that, as of December 31, 2022, our internal control over financial reporting is effective based on those criteria. Ernst & Young LLP, the independent registered public accounting firm that audited our financial statements included in this Form 10-K, has issued an attestation report on our internal control over financial reporting as of December 31, 2022. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. (c) Attestation Report of the Independent Registered Public Accounting Firm. 55 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and the Board of Directors of Repligen Corporation: Opinion on Internal Control over Financial Reporting We have audited Repligen Corporation’s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Repligen Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of comprehensive income, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and our report dated February 22, 2023 expressed an unqualified opinion thereon. Basis for Opinion The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Report of Management on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Definition and Limitations of Internal Control Over Financial Reporting A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. /s/ Ernst & Young LLP Boston, Massachusetts February 22, 2023 56 (d) Changes in Internal Control Over Financial Reporting There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. ITEM 9B. OTHER INFORMATION None. ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS Not applicable. 57 PART III Pursuant to General Instructions G to Form 10-K, the information required for Part III, Items 10, 11, 12, 13 and 14, is incorporated herein by reference from the Company’s proxy statement for the 2023 Annual Meeting of Stockholders. 58 PART IV ITEM 15. EXHIBITS AND FINAN CIAL STATEMENT SCHEDULES The following documents are filed as part of this Form 10-K: (a) (1) Financial Statements : The financial statements required by this item are submitted in a separate section beginning on page 65 of this report, as follows: Page Report of Independent Registered Public Accounting Firm 66 Consolidated Balance Sheets as of December 31, 2022 and December 31, 2021 68 Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2022, 2021 and 2020 69 Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2022, 2021 and 2020 70 Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2021 and 2020 71 Notes to Consolidated Financial Statements 72 (a) (2) Financial Statement Schedules : None. (a) (3) Exhibits : The Exhibits which are filed as part of this Form 10-K or which are incorporated by reference are set forth in the Exhibit Index hereto. 59 EXHIBIT INDEX Exhibit Number Document Description 2.1# Stock Purchase Agreement, dated April 25, 2019, by and among Repligen Corporation, C Technologies and Craig Harrison (filed as Exhibit 2.1 to Repligen Corporation’s Current Report on Form 8-K filed on April 26, 2019 and incorporated herein by reference). 3.1 Restated Certificate of Incorporation dated June 30, 1992, as amended September 17, 1999 (filed as Exhibit 3.1 to Repligen Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 1999 and incorporated herein by reference). 3.2 Certificate of Amendment to the Certificate of Incorporation of Repligen Corporation, effective as of May 16, 2014 (filed as Exhibit 3.1 to Repligen Corporation’s Current Report on Form 8-K filed on May 19, 2014 and incorporated herein by reference). 3.3 Third Amended and Restated Bylaws (filed as Exhibit 3.1 to Repligen Corporation’s Current Report on Form 8-K filed on January 28, 2021 and incorporated herein by reference). 4.1 Specimen Stock Certificate (filed as Exhibit 4.1 to Repligen Corporation’s Annual Report on Form 10-K for the year ended March 31, 2002 and incorporated herein by reference). 4.2 Base Indenture, dated as of July 19, 2019, by and between Repligen Corporation and Wilmington Trust, National Association (filed as Exhibit 4.1 to Repligen Corporation’s Current Report on Form 8-K filed on July 22, 2019 and incorporated herein by reference). 4.3 First Supplemental Indenture, dated as of July 19, 2019, by and between Repligen Corporation and Wilmington Trust, National Association (filed as Exhibit 4.2 to Repligen Corporation’s Current Report on Form 8-K filed on July 22, 2019 and incorporated herein by reference). 4.4 Second Supplemental Indenture, dated as of March 4, 2022, by and between Repligen Corporation and Wilmington Trust, National Association, as trustee (filed as Exhibit 4.1 to Repligen Corporation's Form 8-K filed on March 8, 2022). 4.5 Form of 0.375% Convertible Senior Note due 2024 (included in Exhibit 4.3). 4.6 Description of Certain Registrant’s Securities (filed as Exhibit 4.5 to Repligen Corporation’s Annual Report on Form 10-K for the year ended December 31, 2019 and incorporated by reference). 10.1* Repligen Executive Incentive Compensation Plan (filed as Exhibit 10.1 to Repligen Corporation’s Current Report on Form 8-K filed on December 14, 2005 and incorporated herein by reference). 10.2* Second Amended and Restated 2001 Repligen Corporation Stock Plan (filed as Exhibit 10.1 to Repligen Corporation’s Current Report on Form 8-K filed on September 18, 2008 and incorporated herein by reference). 10.3.1* Amended and Restated 2001 Repligen Corporation Stock Option Plan, Form of Incentive Stock Option Agreement (filed as Exhibit 10.14 to Repligen Corporation’s Annual Report on Form 10-K for the year ended March 31, 2005 and incorporated herein by reference). 10.3.2* Amended and Restated 2001 Repligen Corporation Stock Plan, Form of Restricted Stock Agreement (filed as Exhibit 10.1 to Repligen Corporation’s Current Report on Form 8-K filed on January 9, 2006 and incorporated herein by reference). 10.4 Lease Between Repligen Corporation as Tenant and West Seyon LLC as Landlord, 35 Seyon Street, Waltham, MA (as amended to date) (filed as Exhibit 10.4 to Repligen Corporation’s Annual Report on Form 10-K for the year ended December 31, 2019 and incorporated herein by reference). 60 10.5# Strategic Supplier Alliance Agreement dated January 28, 2010 by and between Repligen Corporation and GE Healthcare Bio-Sciences AB (as amended to date) (filed as Exhibit 10.1 to Repligen Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and incorporated herein by reference). 10.6* Repligen Corporation Amended and Restated 2012 Stock Option and Incentive Plan (filed as Exhibit 99.1 to Repligen Corporation’s Form S-8 filed on June 2, 2014 and incorporated herein by reference). 10.7* Letter Agreement, dated as of June 10, 2014, by and between Repligen Corporation and Jon K. Snodgres (filed as Exhibit 10.1 to Repligen Corporation’s Current Report on Form 8-K filed on July 15, 2014 and incorporated herein by reference). 10.8*+ Repligen Corporation Amended and Restated Non-Employee Directors' Compensation Policy. 10.9 Form of Indemnification Agreement (filed as Exhibit 10.1 to Repligen Corporation’s Current Report on Form 8-K filed on May 12, 2016 and incorporated herein by reference). 10.10 Lease Agreement, dated February 6, 2018, by and between Repligen Corporation and U.S. REIF 111 Locke Drive Massachusetts, LLC (filed as Exhibit 10.1 to Repligen Corporation’s Current Report on Form 8-K filed on February 8, 2018 and incorporated herein by reference). 10.11* 2018 Repligen Corporation Stock Option and Incentive Plan (filed as Exhibit 10.1 to Repligen Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 and incorporated herein by reference). 10.12* Letter Agreement, dated as of September 3, 2016 by and between Repligen Corporation and Ralf Kuriyel (filed as Exhibit 10.17 to Repligen Corporation’s Annual Report on Form 10-K for the year ended December 31, 2018 and incorporated herein by reference). 10.13* Repligen Corporation Amended and Restated Severance and Change in Control Plan, effective as of May 26, 2022 (filed as Exhibit 10.1 to Repligen Corporation's Form 8-K filed June 1, 2022). 10.14* Third Amendment and Restated Employment Agreement, dated as of May 26, 2022, by and between Repligen Corporation and Tony J. Hunt (filed as Exhibit 10.2 to Repligen Corporation's Form 8-K filed June 1, 2022). 10.15 First Amendment to Lease Agreement, dated as of July 7, 2020 by and between Repligen Corporation and U.S. REIF 111 Locke Drive Massachusetts, LLC (filed as Exhibit 10.1 to Repligen Corporation’s Current Report on Form 8-K filed on July 10, 2020 and incorporated herein by reference). 10.16* Repligen Corporation 2018 Stock Option and Incentive Plan, Sub-Plan for French-Qualified Restricted Stock Units (filed as Exhibit 10.1 to Repligen Corporation’s Form 10-Q for the quarter ended June 30, 2021 and incorporated herein by reference). 21.1+ Subsidiaries of the Registrant. 23.1+ Consent of Ernst & Young LLP, Independent Registered Accounting Firm. 24.1+ Power of Attorney (included on signature page). 31.1+ Rule 13a-14(a)/15d-14(a) Certification. 31.2+ Rule 13a-14(a)/15d-14(a) Certification. 32.1+ Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS+ Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH+ Inline XBRL Taxonomy Extension Schema Document. 101.CAL+ Inline XBRL Taxonomy Extension Calculation Linkbase Document. 61 101.DEF+ Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB+ Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE+ Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104+ Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*). # Confidential treatment obtained as to certain portions. * Management contract or compensatory plan or arrangement. + Filed electronically herewith. The exhibits listed above are not contained in the copy of the Annual Report on Form 10-K distributed to stockholders. Upon the request of any stockholder entitled to vote at the 2023 Annual Meeting, the Registrant will furnish that person without charge a copy of any exhibits listed above. Requests should be addressed to Repligen Corporation, 41 Seyon Street, Waltham, MA 02453. ITEM 16. 10 -K SUMMARY We may voluntarily include a summary of information required by Form 10-K under Item 16. We have elected not to include such summary information. 62 SIGNAT URES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REPLIGEN CORPORATION Date: February 22, 2023 By: / S / T ONY J. H UNT Tony J. Hunt President and Chief Executive Officer 63 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby makes, constitutes and appoints Tony J. Hunt and Jon K. Snodgres with full power to act without the other, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities to sign any or all amendments to this Form 10-K, and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents of any of them, or any substitute or substitutes, lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. Signature Title Date / S / T ONY J. H UNT Tony J. Hunt President, Chief Executive Officer and Director (Principal executive officer) February 22, 2023 / S / J ON K. S NODGRES Jon K. Snodgres Chief Financial Officer (Principal financial and accounting officer) February 22, 2023 / S / K AREN D AWES Karen Dawes Chairperson of the Board February 22, 2023 / S / N ICOLAS M. B ARTHELEMY Nicolas M. Barthelemy Director February 22, 2023 / S / C ARRIE E GLINTON M ANNER Carrie Eglinton Manner Director February 22, 2023 /S/ K ONSTANTIN K ONSTANTINOV Konstantin Konstantinov Director February 22, 2023 / S / M ARTIN D. M ADAUS Martin D. Madaus Director February 22, 2023 / S / R OHIN M HATRE Rohin Mhatre Director February 22, 2023 / S / G LENN P. M UIR Glenn P. Muir Director February 22, 2023 64 INDEX TO FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm 66 Consolidated Balance Sheets as of December 31, 2022 and December 31, 2021 68 Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2022, 2021 and 2020 69 Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2022, 2021 and 2020 70 Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2021 and 2020 71 Notes to Consolidated Financial Statements 72 65 REPORT OF INDEPENDENT REGIST ERED PUBLIC ACCOUNTING FIRM To the Stockholders and the Board of Directors of Repligen Corporation: Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Repligen Corporation (the Company) as of December 31, 2022 and 2021, the related consolidated statements of comprehensive income, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 22, 2023 expressed an unqualified opinion thereon. Adoption of ASU No. 2020-06 As discussed in Note 2 to the consolidated financial statements, the Company changed its method for accounting for convertible debt in 2022 due to the adoption of ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20). Basis for Opinion These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the US federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matter The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. Valuation of contingent consideration Description of the Matter As disclosed in Note 4 to the consolidated financial statements under the caption “Acquisitions” and Note 3 under the caption “Fair Value Measurements”, during 2021, the Company completed the acquisition of Avitide, Inc. for consideration of approximately $246.3 million, net of cash acquired. The Company recognized a contingent consideration liability at the estimated fair value on the acquisition date in 66 connection with applying the acquisition accounting for business combinations. Subsequent changes to the fair value of the contingent consideration liability are recorded within the consolidated statement of comprehensive income in the period of change. At December 31, 2022, the Company had a $65.5 million contingent consideration liability, which represented a ‘Level 3’ fair value measurement in the fair value hierarchy due to the significant unobservable inputs used in determining the fair value and the use of management judgement about the assumptions market participants would use in pricing the liability. Auditing the Company's accounting for its contingent consideration liability was complex and required significant auditor judgment due to the use of a Monte Carlo simulation model and the high degree of subjectivity in evaluating certain assumptions required to estimate the fair value of contingent payments. In particular, the fair value measurement was sensitive to the significant assumptions underlying future revenue and production forecasts, as well as, the probability of achieving such forecasts. These significant assumptions are forward looking and could be affected by future economic and market conditions. How We Addressed the Matter in Our Audit We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company's contingent consideration liability process including, among others, management's process to establish the significant assumptions and measure the liability. Our tests included controls over management's review of assumptions used in the valuation model. To test the estimated fair value of the contingent consideration liability, our audit procedures included, among others, inspecting the terms of the executed purchase agreement, assessing the Monte Carlo simulation model used and testing the key contractual inputs and significant assumptions discussed above. We performed audit procedures that included, among others, evaluating the Company's selection of the valuation methodology, evaluating the methods and significant assumptions used by the Company, and evaluating the completeness and accuracy of the underlying data supporting the significant assumptions and estimates. This includes comparing the significant assumptions to current industry, market and economic trends, to the historical results of the acquired business and to other guidelines used by companies within the same industry. We involved our valuation professionals to assist in our evaluation of the methodology used by the Company and significant assumptions included in the fair value estimates. /s/ Ernst & Young LLP We have served as the Company’s auditor since 2002 Boston, Massachusetts February 22, 2023 67 REPLIGEN CORPORATION CONSOLIDATED B ALANCE SHEETS (Amounts in thousands, except share data) December 31, December 31, 2022 2021 ASSETS Current assets: Cash and cash equivalents $ 523,458 $ 603,814 Marketable securities held to maturity 100,299 — Accounts receivable, net of reserves of $ 1,365 and $ 1,417 at December 31, 2022 and December 31, 2021, respectively 116,247 117,420 Inventories, net 238,277 184,494 Prepaid expenses and other current assets 19,837 25,949 Total current assets 998,118 931,677 Noncurrent assets: Property, plant and equipment, net 190,673 124,964 Intangible assets, net 353,676 337,274 Goodwill 855,513 860,362 Deferred tax assets 840 1,903 Operating lease right of use assets 125,023 101,559 Other noncurrent assets 815 615 Total noncurrent assets 1,526,540 1,426,677 Total assets $ 2,524,658 $ 2,358,354 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 27,554 $ 36,203 Operating lease liability 6,957 8,303 Current contingent consideration 13,950 — Accrued liabilities 71,120 75,498 Convertible Senior Notes, net 284,615 255,258 Total current liabilities 404,196 375,262 Noncurrent liabilities: Deferred tax liabilities 23,000 33,480 Noncurrent operating lease liability 131,389 102,492 Noncurrent contingent consideration 51,559 94,238 Other noncurrent liabilities 3,814 2,815 Total noncurrent liabilities 209,762 233,025 Total liabilities 613,958 608,287 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock, $ 0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding — — Common stock, $ 0.01 par value; 80,000,000 shares authorized; 55,557,698 shares at December 31, 2022 and 55,321,457 shares at December 31, 2021 issued and outstanding 556 553 Additional paid-in capital 1,547,266 1,572,340 Accumulated other comprehensive loss ( 34,394 ) ( 16,886 ) Accumulated earnings 397,272 194,060 Total stockholders’ equity 1,910,700 1,750,067 Total liabilities and stockholders’ equity $ 2,524,658 $ 2,358,354 The accompanying notes are an integral part of these consolidated financial statements. 68 REPLIGEN CORPORATION CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Amounts in thousands, except per share data) For the Years Ended December 31, 2022 2021 2020 Revenue: Products $ 801,183 $ 670,319 $ 366,136 Royalty and other revenue 353 215 124 Total revenue 801,536 670,534 366,260 Costs and operating expenses: Cost of product revenue 345,830 279,280 156,634 Research and development 43,936 34,274 20,182 Selling, general and administrative 215,829 183,866 119,621 Contingent consideration ( 28,729 ) 5,865 — Total costs and operating expenses 576,866 503,285 296,437 Income from operations 224,670 167,249 69,823 Other (expenses) income: Investment income 6,978 176 1,741 Interest expense ( 1,162 ) ( 11,278 ) ( 10,768 ) Amortization of debt issuance costs ( 1,815 ) ( 1,436 ) ( 1,365 ) Other expenses ( 9,531 ) ( 1,168 ) ( 214 ) Other expenses, net ( 5,530 ) ( 13,706 ) ( 10,606 ) Income before income taxes 219,140 153,543 59,217 Income tax provision (benefit) 33,181 25,252 ( 709 ) Net income $ 185,959 $ 128,291 $ 59,926 Earnings per share: Basic $ 3.35 $ 2.33 $ 1.14 Diluted $ 3.24 $ 2.24 $ 1.11 Weighted average common shares outstanding: Basic 55,460 55,015 52,554 Diluted 57,455 57,264 53,892 Net income $ 185,959 $ 128,291 $ 59,926 Other comprehensive income (loss): Foreign currency translation adjustment ( 17,508 ) ( 18,971 ) 17,112 Comprehensive income $ 168,451 $ 109,320 $ 77,038 The accompanying notes are an integral part of these consolidated financial statements. 69 REPLIGEN CORPORATION CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Amounts in thousands, except share data) Common Stock Number of Shares (#) Par Value Additional Paid-In Capital Accumulated Other Comprehensive Income (Loss) Accumulated Earnings/ (Deficit) Total Stockholders' Equity Balance at December 31, 2019 52,078,258 $ 521 $ 1,068,431 $ ( 15,027 ) $ 5,843 $ 1,059,768 Net income — — — — 59,926 59,926 Exercise of stock options and vesting of stock units 584,589 6 8,134 — — 8,140 Issuance of common stock pursuant to the acquisition of ARTeSYN Biosolutions 372,990 4 69,418 — — 69,422 Proceeds from issuance of common stock, net of issuance costs of $ 0.4 million 1,725,000 17 297,758 — — 297,775 Stock-based compensation expense — — 17,007 — — 17,007 Translation adjustment — — — 17,112 — 17,112 Balance at December 31, 2020 54,760,837 $ 548 $ 1,460,748 $ 2,085 $ 65,769 $ 1,529,150 Net income — — — — 128,291 128,291 Issuance of common stock for debt conversion 7 0 2 — — 2 Exercise of stock options and vesting of stock units 300,721 3 3,876 — — 3,879 Issuance of common stock pursuant to the acquisition of Avitide Inc. 271,096 2 82,966 — — 82,968 Tax withholding on vesting of restricted stock ( 11,204 ) ( 0 ) ( 2,897 ) — — ( 2,897 ) Stock-based compensation expense — — 27,500 — — 27,500 True-up of costs related to the December 2020 issuance of common stock — — 145 — — 145 Translation adjustment — — — ( 18,971 ) — ( 18,971 ) Balance at December 31, 2021 55,321,457 $ 553 $ 1,572,340 $ ( 16,886 ) $ 194,060 $ 1,750,067 Net income — — — — 185,959 185,959 Issuance of common stock for debt conversion 21 1 ( 7 ) — — ( 6 ) Exercise of stock options and vesting of stock units 326,192 3 3,704 — — 3,707 Tax withholding on vesting of restricted stock ( 89,972 ) ( 1 ) ( 17,017 ) — — ( 17,018 ) Stock-based compensation expense — — 27,316 — — 27,316 Impact of the adoption of ASU 2020-06 — — ( 39,070 ) — 17,253 ( 21,817 ) Translation adjustment — — — ( 17,508 ) — ( 17,508 ) Balance at December 31, 2022 55,557,698 $ 556 $ 1,547,266 $ ( 34,394 ) $ 397,272 $ 1,910,700 The accompanying notes are an integral part of these consolidated financial statements. 70 REPLIGEN CORPORATION CONSOLIDATED STATEM ENTS OF CASH FLOWS (Amounts in thousands) For the Years Ended December 31, 2022 2021 2020 Cash flows from operating activities: Net income $ 185,959 $ 128,291 $ 59,926 Adjustments to reconcile net income to net cash provided by operating activities: Inventory step-up charges — 2,130 734 Depreciation and amortization 50,985 38,447 27,067 Amortization of debt discount and issuance costs 1,815 11,530 10,970 Stock-based compensation expense 27,316 27,500 17,007 Contingent consideration expense ( 28,729 ) 5,865 — Deferred income taxes, net ( 1,352 ) 6,517 ( 3,992 ) Other ( 100 ) 864 267 Changes in operating assets and liabilities, excluding impact of acquisitions: Accounts receivable ( 3,596 ) ( 46,523 ) ( 20,892 ) Inventories ( 57,204 ) ( 89,781 ) ( 29,994 ) Prepaid expenses and other assets 2,396 ( 10,192 ) ( 4,870 ) Operating lease right of use assets ( 24,549 ) ( 4,315 ) 3,583 Other assets ( 231 ) 430 175 Accounts payable ( 8,197 ) 19,523 2,462 Accrued expenses ( 2,019 ) 23,196 1,037 Operating lease liability 28,623 6,958 ( 1,964 ) Long-term liabilities 966 ( 1,424 ) 1,109 Total cash provided by operating activities 172,083 119,016 62,625 Cash flows from investing activities: Purchase of marketable securities held to maturity ( 100,000 ) — — Additions to capitalized software costs ( 3,512 ) ( 4,187 ) ( 3,889 ) Acquisitions, net of cash acquired — ( 149,893 ) ( 175,041 ) Purchases of property, plant and equipment ( 84,834 ) ( 67,089 ) ( 22,455 ) Purchase of intellectual property ( 45,000 ) — — Other investing activities 110 — — Total cash used in investing activities ( 233,236 ) ( 221,169 ) ( 201,385 ) Cash flows from financing activities: Proceeds from issuance of common stock, net of issuance costs — — 297,775 Proceeds from exercise of stock options 3,707 3,879 8,151 Repayment of Convertible Senior Notes ( 26 ) ( 21 ) — Payment of tax withholding obligation on vesting of restricted stock ( 17,018 ) ( 2,897 ) ( 10 ) Total cash (used in) provided by financing activities ( 13,337 ) 961 305,916 Effect of exchange rate changes on cash, cash equivalents and restricted cash ( 5,866 ) ( 12,286 ) 12,729 Net (decrease) increase in cash, cash equivalents and restricted cash ( 80,356 ) ( 113,478 ) 179,885 Cash, cash equivalents and restricted cash, beginning of period 603,814 717,292 537,407 Cash and cash equivalents, end of period $ 523,458 $ 603,814 $ 717,292 Supplemental disclosure of cash flow information: Income taxes paid $ 34,365 $ 16,515 $ 10,279 Interest paid $ 1,033 $ 1,066 $ 1,066 Supplemental disclosure of non-cash investing and financing activities: Assets acquired under operating leases $ 29,126 $ 85,312 $ 3,349 Fair value of 271,096 shares of common stock issued for acquisition of Avitide, Inc. $ — $ 82,968 $ — Fair value of earnouts related to the acquisition of Avitide, Inc. $ — $ 94,238 $ — Fair value of 372,990 shares of common stock issued for acquisition of ARTeSYN Biosolutions Holdings Ireland Limited $ — $ — $ 69,422 The accompanying notes are an integral part of these consolidated financial statements. 71 REPLIGEN CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 1. Organization and Nature of Business Repligen Corporation (NASDAQ:RGEN) is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The Company’s franchises include filtration, chromatography, process analytics and proteins. See Part I, Item 1. "Business - Our Products", of this report for additional information related to the Company's products. The Company’s bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. The Company operates under one reportable segment. The Company’s chief operating decision maker (“CODM”) reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. See Note 2, “Summary of Significant Accounting Policies – Segment Reporting,” for more information on the Company’s segment. A majority of our 18 manufacturing sites are located in the United States (California, Massachusetts, New Hampshire, New Jersey, New York and Texas). Outside the United States, we have manufacturing sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. The Company is subject to a number of risks typically associated with companies in the biotechnology industry. These risks principally include the Company’s dependence on key customers, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with the U.S. Food and Drug Association and other governmental regulations and approval requirements, as well as the ability to grow the Company’s business and obtain adequate funding to finance this growth. 2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions by management affect the Company’s revenue recognition for multiple element arrangements, allowance for credit losses, the net realizable value of inventory, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, contingent consideration, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB, Repligen GmbH, Spectrum LifeSciences LLC and its subsidiaries (“Spectrum”), C Technologies, Inc. ("C Technologies"), ARTeSYN Biosolutions Holdings Ireland Ltd., ARTeSYN Biosolutions Ireland Limited and its subsidiaries (“ARTeSYN”), Polymem S.A. (“Polymem”), Avitide, LLC (“Avitide”), Newton T&M Corp ("NTM"), Bio-Flex Solutions, LLC ("BioFlex"), Repligen Singapore Pte. Ltd. and Repligen UK Limited. All significant intercompany accounts and transactions have been eliminated in consolidation. Certain prior year balances have changed to reflect current year presentation. 72 Foreign Currency The Company translates the assets and liabilities of its foreign subsidiary at rates in effect at the end of the reporting period. Revenues and expenses are translated at average rates in effect during the reporting period. Translation adjustments, including adjustments related to the Company’s various intercompany loans. Any intercompany loans with foreign subsidiaries are remeasured at each period end and included in accumulated other comprehensive loss on the consolidated balance sheets. Revenue Recognition We generate revenue from the sale of bioprocessing products, equipment devices, and related consumables used with these equipment devices to customers in the life sciences and biopharmaceutical industries. Under Accounting Standard Codification No. (“ASC”) 606, “ Revenue from Contracts with Customers,” revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”). To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of December 31, 2022. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The Company recognizes product revenue under the terms of each customer agreement upon transfer of control to the customer, which occurs at a point in time. Shipping and handling fees are recorded as a component of product revenue, with the associated costs recorded as a component of cost of product revenue. Risks and Uncertainties The Company evaluates its operations periodically to determine if any risks and uncertainties exist that could impact its operations in the near term. The Company does not believe that there are any significant risks that have not already been disclosed in the consolidated financial statements. A loss of certain suppliers could temporarily disrupt operations, although alternate sources of supply exist for these items. The Company has mitigated these risks by working closely with key suppliers, identifying alternate sources and developing contingency plans. Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents include cash on hand and on deposit. Highly liquid investments in money market mutual funds with an original maturity of three months or less are classified as cash equivalents. All cash equivalents are carried at cost, which 73 approximates fair value. Restricted cash represents cash that is restricted as to withdrawal or usage. There was no restriction on the Company’s cash balance as of December 31, 2022 and 2021. The Company’s cash, cash equivalents and restricted cash total as presented in the Company’s consolidated statements of cash flows for the years ended December 31, 2022, 2021 and 2020 was $ 523.5 million, $ 603.8 million and $ 717.3 million, respectively. The beginning cash, cash equivalents and restricted cash balance of $ 537.4 million on the consolidated statement of cash flows for the year ended December 31, 2020 includes $ 9.0 million in restricted cash, which represented cash held and due to employees based on their continued employment with the Company one year after the acquisition of C Technologies in 2019. The amount was subsequently paid to employees during 2020. I nvestment Securities We classify our investment securities in one of three categories: held to maturity, trading, or available for sale. Our investment portfolio at December 31, 2022 consists of an investment in U.S. treasury bills classified as held to maturity which is included in the Company's consolidated balance sheets under marketable securities held to maturity. Securities that we have the positive intent and ability to hold to maturity are classified as held to maturity and stated at amortized cost in the consolidated balance sheet. Management determines the appropriate classification of securities at the time of purchase based upon management's intent with regards to such investment and reevaluates such designation as of each balance sheet date. The Company's investment policy requires that it only invest in high rated securities and limit its exposure to any single-user. Currently, all investment securities are held-to-maturity and are carried at amortized cost on the Company's consolidated balance sheet as of December 31, 2022, as marketable securities held to maturity. There were no realized or unrealized gains or losses on investments recorded as of December 31, 2022, 2021 and 2020. The Company classifies marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date. The Company periodically assesses its marketable securities for impairment or credit losses. Fair Value Measurement In determining the fair value of its assets and liabilities, the Company uses various valuation approaches. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 – Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. 74 Allowance for credit losses We establish an allowance for credit losses through a review of several factors, including historical collection experience, current aging status of the customer accounts, and current financial condition of our customers. Losses are charged against the allowance when the customer accounts are determined to be uncollectible. Inventories Inventories relate to the Company’s bioprocessing business. The Company values inventory at cost or, if lower, net realizable value, using the first-in, first-out method. The Company reviews its inventories at least quarterly and records a provision for excess and obsolete inventory based on its estimates of expected sales volume, production capacity and expiration dates of raw materials, work-in-process and finished products. The Company writes down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements to cost of product revenue. Manufacturing of bioprocessing finished goods is done to order and tested for quality specifications prior to shipment. A change in the estimated timing or amount of demand for the Company’s products could result in additional provisions for excess inventory quantities on hand. Any significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results. During all periods presented in the accompanying consolidated financial statements, there have been no material adjustments related to a revised estimate of inventory valuations. Work-in-process and finished products inventories consist of material, labor, outside processing costs and manufacturing overhead. Lease Accounting The Company adopted Accounting Standards Update No. ("ASU") 2016-02, “Leases (Topic 842) ” (“ASC 842”) as of January 1, 2019. Under ASC 842, the Company determines whether the arrangement contains a lease at the inception of an arrangement. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its consolidated balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases. Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company does not separate lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option. Finance leases are recorded in property, plant and equipment, net, other current liabilities and long-term finance lease liabilities and operating leases are recorded in operating lease right of use assets, operating lease liability and operating lease liability, long-term on the Company’s consolidated balance sheet. 75 Certain of the Company’s operating leases where the Company is the lessee provide for minimum annual payments that increase over the life of the lease. Some of these leases include obligations to pay for other services, such as operations and maintenance. For leases of property, the Company accounts for these other services as a component of the lease. The aggregate minimum annual payments are expensed on the straight-line basis beginning when the Company takes possession of the property and extending over the term of the related lease, including renewal options when the exercise of the option is reasonably certain as an economic penalty may be incurred if the option is not exercised. The Company also accounts in its straight-line computation for the effect of any “rental holidays.” Operating lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of the fixed lease payments, reduced by landlord incentives using a discount rate based on similarly secured borrowings available to the Company. Most of the leases do not provide implicit interest rates and therefore the Company determines the discount rate based on its incremental borrowing rate. The incremental borrowing rate for the Company’s leases is determined based on lease term and currency in which the lease payments are made. Accrued Liabilities The Company estimates accrued liabilities by identifying services performed on the Company’s behalf, estimating the level of service performed and determining the associated cost incurred for such service as of each balance sheet date. For example, the Company would accrue for professional and consulting fees incurred with law firms, audit and accounting service providers and other third-party consultants. These expenses are determined by either requesting those service providers to estimate unbilled services at each reporting date for services incurred or tracking costs incurred by service providers under fixed fee arrangements. The Company has processes in place to estimate the appropriate amounts to record for accrued liabilities, which principally involve the applicable personnel reviewing the services provided. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under or over-estimates the level of services performed or the costs of such services, the reported expenses for that period may be too low or too high. The date on which certain services commence, the level of services performed on or before a given date, and the cost of such services often require the exercise of judgment. The Company makes these judgments based upon the facts and circumstances known at the date of the financial statements. Income Taxes Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates this tax position on a quarterly basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense. The Company is subject to a territorial tax system under the Tax Cuts and Jobs Act enacted in December 2017, in which the Company is required to provide for tax on Global Intangible Low-Taxed Income ("GILTI") earned by certain foreign subsidiaries. The Company has adopted an accounting policy to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. 76 Property, Plant & Equipment Property, plant & equipment is recorded at cost less allowances for depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the asset as follows: Classification Estimated Useful Life Buildings Thirty years Leasehold improvements Shorter of the term of the lease or estimated useful life Equipment Three to twelve years Furniture, fixtures and office equipment Three to eight years Computer hardware and software Three to seven years or estimated useful life Upon disposal of property, plant & equipment, the cost of the asset and the accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in our results of operations. Fully depreciated assets are not removed from the accounts until they are physically disposed of. Certain systems development costs related to the purchase, development and installation of computer software developed or obtained for internal use are capitalized and depreciated over the estimated useful life of the related project. Costs incurred prior to the development stage, as well as maintenance, training costs, and general and administrative expenses are expensed as incurred. Earnings Per Share The Company reports earnings per share ("EPS") in accordance with ASC 260, "Earnings Per Share," which establishes standards for computing and presenting EPS. Basic EPS is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS is computed by dividing net income available to common shareholders by the weighted-average number of common shares and dilutive common share equivalents outstanding during the period. Potential common share equivalents consist of restricted stock awards (including performance stock units) and the incremental common shares issuable upon the exercise of stock options and warrants. Under the treasury stock method, unexercised “in-the-money” stock options are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period. In periods when the Company has a net loss, stock awards are excluded from the calculation of earnings per share as their inclusion would have an antidilutive effect. 77 A reconciliation of basic and diluted weighted average share outstanding is as follows: For the Years Ended December 31, 2022 2021 2020 (Amounts in thousands, except per share data) Numerator: Net income $ 185,959 $ 128,291 $ 59,926 Effect of dilutive securities: Charges associated with convertible debt instruments, net of tax 387 — — Numerator for diluted earnings per share - net income available to common stockholders after the effect of dilutive securities $ 186,346 $ 128,291 $ 59,926 Denominator: Weighted average shares used in computing net income per share - basic 55,460 55,015 52,554 Effect of dilutive shares: Options and stock units 608 915 971 Convertible senior notes 1,360 1,253 367 Contingent consideration 11 — — Dilutive effect of unvested performance stock units 16 81 — Dilutive potential common shares 1,995 2,249 1,338 Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted 57,455 57,264 53,892 Earnings per share: Basic $ 3.35 $ 2.33 $ 1.14 Diluted $ 3.24 $ 2.24 $ 1.11 For the years ended December 31, 2022, 2021 and 2020 , 177,318 shares, 68,968 shares and 98,048 shares, respectively, of the Company’s common stock were excluded from the calculation of diluted earnings per share because they would have had an anti-dilutive effect for years presented. In July 2019, the Company issued $ 287.5 million aggregate principal amount of our 0.375% Convertible Senior Notes due 2024 (the "2019 Notes"). As provided by the terms of the indenture underlying the 2019 Notes, prior to March 4, 2022, conversion of the 2019 Notes could have been settled in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. On March 4, 2022, we entered into the Second Supplemental Indenture for the 2019 Notes, which irrevocably elected to settle the conversion of the 2019 Notes using a combination of cash and shares of the Company's common stock, settling the par value of the 2019 Notes in cash and any excess conversion premium in shares. As provided by the terms of the Second Supplemental Indenture underlying the 2019 Notes, the Company irrevocably elected to settle the conversion obligation for the 2019 Notes in a combination of cash and shares of the Company's common stock. This means the Company will settle the par value of the 2019 Notes in cash and any excess conversion premium in shares. As mentioned in Note 13, "Convertible Senior Notes," the Company adopted ASU 2020-06 effective January 1, 2022. Under ASU 2020-06, the Company is required to reflect the dilutive effect of the convertible securities by application of the "if-converted" method, which means the denominator of the EPS calculation would include the total number of shares assuming the 2019 Notes had been fully converted at the beginning of the period. Prior to March 4, 2022, the Company had the choice to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 (the date the Company adopted ASU 2020-06) to March 4, 2022, the Company included 3,474,429 shares in the denominator of the EPS calculation, applying the if converted method. Subsequent to March 4, 2022, after the Second Supplemental Indenture became effective, the Company irrevocably elected to settle the conversion obligation for the 2019 Notes in a combination of cash and shares of the Company's common stock, and from March 5, 2022 forward, only the excess premium will be settled with shares. Under the if-converted method of calculating dilutive shares, the Company was also required to exclude amortization of debt issuance costs and interest charges applicable to the convertible debt from the numerator of the dilutive EPS calculation for the period from January 1, 2022 to March 4, 2022, as if the interest on convertible debt was never recognized for that period. For the year ended 78 December 31, 2022, the Company excluded interest charges of $ 0.4 million (net of tax) from the numerator and included 1,359,957 shares in the calculation of diluted earnings as the dilutive effect of the conversion premium. Prior to the adoption of ASU 2020-06, the Company applied the provisions of ASC 260-10-45-44, to determine the diluted weighted average shares outstanding as it related to the conversion spread on its convertible notes. Accordingly, the par value of the 2019 Notes was not included in the calculation of diluted EPS, but the dilutive effect of the conversion premium was considered in the calculation of diluted EPS using the treasury stock method. The dilutive impact of the 2019 Notes was based on the difference between the Company’s current period average stock price and the conversion price of the convertible notes, provided there is a premium. Pursuant to this accounting standard, there was no dilution from the accreted principal of the 2019 Notes. For the years ended December 31, 2021 and 2020, the dilutive effect of the conversion premium included in the calculation of diluted earnings was 1,253,168 shares and 366,534 shares, respectively. Segment Reporting The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. The following table represents product revenues by product line: For the Years Ended December 31, 2022 2021 (1) 2020 (2) (Amounts in thousands) Filtration products $ 495,930 $ 403,505 $ 174,851 Chromatography products (3) 131,680 91,037 70,677 Process analytics products 53,512 48,019 33,346 Proteins products (3) 114,320 123,707 83,317 Other 5,741 4,051 3,945 Total product revenue $ 801,183 $ 670,319 $ 366,136 (1) 2021 revenue for filtration products includes revenue related to Polymem from July 1, 2021, as well as BioFlex and NTM from December 16, 2021 through December 31, 2021. 2021 revenue for proteins products includes revenue related to Avitide from September 20, 2021 through December 31, 2021. (2) 2020 revenue for filtration products includes revenue related to EMT from July 13, 2020, NMS from October 20, 2020, and ARTeSYN from December 3, 2020 through December 31, 2020. (3) Revised 2020 revenue in the table above reflects a shift in product revenue from chromatography products to proteins products of approximately $ 3 million. These changes are consistent with the current year presentation of product revenue. Revenue from filtration products includes the XCell ATF ® systems and consumables as well as the KrosFlo ® and SIUS ® filtration products. Revenue from chromatography products includes the OPUS ® chromatography pre-packed columns ("PPC"), chromatography resins and ELISA test kits. Revenue from process analytics products includes the SoloVPE ® , FlowVPE ® and FlowVPX ® devices. Revenue from protein products includes the Protein A affinity ligands and cell culture growth factors. Other revenue primarily consists of revenue from the sale of operating room products to hospitals as well as freight revenue. The following table represents the Company’s total revenue by our country of domicile (the United States) and other countries where our major subsidiaries are domiciled for the periods presented (based on the location of the customer): For the Years Ended December 31, 2022 2021 2020 Revenue by customers' geographic locations: North America 43 % 41 % 48 % Europe 37 % 40 % 38 % APAC/Other 20 % 19 % 14 % Total revenue 100 % 100 % 100 % 79 The following table represents the Company’s total assets by our country of domicile (the United States) and other countries where our major subsidiaries are domiciled for the periods presented: December 31, 2022 2021 (Amounts in thousands) Total assets by geographic locations: North America $ 2,209,244 $ 2,082,721 Europe 287,543 243,076 APAC 27,871 32,557 Total assets by geographic location $ 2,524,658 $ 2,358,354 The following table represents the Company’s long-lived assets by our country of domicile (the United States) and other countries where our major subsidiaries are domiciled for the periods presented: December 31, 2022 2021 (Amounts in thousands) Long-lived assets by geographic locations: North America $ 275,151 $ 198,436 Europe 38,541 27,168 APAC 2,819 1,534 Total long-lived assets by geographic location $ 316,511 $ 227,138 Concentrations of Credit Risk and Significant Customers Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings, limit its credit exposure to any one issuer (with the exception of U.S. treasury obligations) and type of instrument is limited. At December 31, 2022, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements. Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition. There was no revenue from customers that represented 10 % or more of the Company's total revenue for the year ended December 31, 2022. Revenue from Pfizer Inc. accounted for 10 % of total revenue for the year ended December 31, 2021, and MilliporeSigma accounted for 11 % of total revenues in the year ended December 31, 2020. Significant accounts receivable balances representing 10 % or more of the Company’s total trade accounts receivable balances at December 31, 2022 and 2021 is as follows: December 31, December 31, 2022 2021 Purolite (an Ecolab Inc. company) 13 % N/A Pfizer Inc. N/A 14 % 80 Business Combinations, Goodwill and Intangible Assets Business Combinations Total consideration transferred for acquisitions is allocated to the tangible and intangible assets acquired and liabilities assumed, if any, based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions with respect to intangible assets and deferred revenue. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, the Company’s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company’s consolidated statements of comprehensive income. Any excess of the fair value of the net tangible and intangible assets acquired over the purchase price is recognized in the consolidated statements of comprehensive income. The fair value of contingent consideration includes estimates and judgments made by management regarding the probability that future contingent payments will be made and the extent of royalties to be earned in excess of the defined minimum royalties. Management updates these estimates and the related fair value of contingent consideration at each reporting period. These changes in the fair value of contingent consideration are recorded to contingent consideration expense in our consolidated statements of comprehensive income. For the years ended December 31, 2022 and 2021 , we recorded ($ 28.7 ) million and $ 5.9 million, respectively, of contingent consideration expense related to the change in estimated contingent consideration obligation related to the acquisition of Avitide (the "Avitide Acquisition"). The Company uses the income approach to determine the fair value of certain identifiable intangible assets including customer relationships and developed technology. This approach determines fair value by estimating after-tax cash flows attributable to these assets over their respective useful lives and then discounting these after-tax cash flows back to a present value. The Company bases its assumptions on estimates of future cash flows, expected growth rates, expected trends in technology, etc. Discount rates used to arrive at a present value as of the date of acquisition are based on the time value of money and certain industry-specific risk factors. The Company believes the estimated purchased customer relationships, developed technologies, trademark/tradename, patents, non-compete agreements and in-process research and development ("R&D") amounts so determined represent the fair value at the date of acquisition, and do not exceed the amount a third-party would pay for such assets. Goodwill Goodwill is not amortized and is tested for impairment at least annually at the reporting unit level. The Company operates as one reporting unit as of the goodwill impairment measurement date of December 31, 2022. During the qualitative assessment of the Company’s one reporting unit during the 2022 goodwill impairment testing, it was determined that it was not more likely than not that its fair value was less than its carrying amount. As such, a quantitative impairment assessment was not required as of December 31, 2022. If an event occurs or circumstances change that would more likely than not reduce the fair value of its reporting unit below its carrying value, the Company will evaluate its goodwill for impairment between annual tests. There was no impairment to goodwill and therefore no impairment charge recorded for the years ended December 31, 2022, 2021 and 2020. Intangible Assets Intangible assets with a definite life are amortized over their useful lives using the straight-line method and the amortization expense is recorded within cost of product revenue, research and development and selling, general and administrative expense in the consolidated statements of comprehensive income. Intangible assets and their related useful lives are reviewed at least annually to determine if any adverse conditions existed that would indicate the carrying value of these assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for the Company’s products or changes in the size of the market for the Company’s products. If impairment indicators are present, the Company determines whether the underlying 81 intangible asset is recoverable through estimated future undiscounted cash flows. If the asset is not found to be recoverable, it is written down to the estimated fair value of the asset based on the sum of the future discounted cash flows expected to result from the use and disposition of the asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. The Company continues to believe that its definite-lived intangible assets are recoverable at December 31, 2022. Indefinite-lived intangible assets are reviewed for impairment at least annually. There has been no impairment of our intangible assets for the periods presented. Stock Based Compensation The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award and recognizes it as an expense over the employee’s requisite service period on a straight-line basis. The Company records the expense for share-based awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates whether the achievement of a performance-based milestone is probable as of the reporting date. The Company has no awards that are subject to market conditions. The Company recognizes stock-based compensation expense based upon options that are ultimately expected to vest, and accordingly, such compensation expense has been adjusted by an amount of estimated forfeitures. The Company uses the Black-Scholes option pricing model to calculate the fair value of share-based awards on the grant date. The following assumptions are used in calculating the fair value of share-based awards: Expected term – The expected term of options granted represents the period of time for which the options are expected to be outstanding. For purposes of estimating the expected term, the Company has aggregated all individual option awards into one group as the Company does not expect substantial differences in exercise behavior among its employees. Expected volatility – The expected volatility is a measure of the amount by which the Company’s stock price is expected to fluctuate during the expected term of options granted. The Company determines the expected volatility based primarily upon the historical volatility of the Company’s common stock over a period commensurate with the option’s expected term. Risk-free interest rate – The risk-free interest rate is the implied yield available on U.S. treasury zero-coupon issues with a remaining term equal to the option’s expected term on the grant date. Expected dividend yield – The Company has never declared or paid any cash dividends on any of its capital stock and does not expect to do so in the foreseeable future. Accordingly, the Company uses an expected dividend yield of zero to calculate the grant-date fair value of a stock option. Estimated forfeiture rates – The Company has applied, based on an analysis of its historical forfeitures, annual forfeiture rates of 8 % for awards granted to non-executive level employees, 3 % for awards granted to executive level employees and 0 % for awards granted to non-employee members of the Board of Directors to all unvested stock options as of December 31, 2022 . The Company reevaluates this analysis periodically and adjusts these estimated forfeiture rates as necessary. Ultimately, the Company will only recognize an expense for those shares that vest. Advertising Costs The Company expenses advertising costs as they are incurred. Advertising expense for the years ended December 31, 2022, 2021 and 2020 was $ 0.6 million, $ 0.6 million and $ 0.3 million, respectively. Recent Accounting Standards Updates We consider the applicability and impact of all ASUs on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued Accounting Standards Updates that we feel may be applicable to the Company are as follows: 82 Recently Issued Accounting Standard Updates – Adopted During the Fiscal Year Effective January 1, 2022, the Company adopted ASU 2020-06, “ Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)” using the modified retrospective method of adoption. ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the primary contract. Consequently, a convertible instrument is now accounted for as a single liability measured at its amortized cost as long as no other features of such convertible instrument require bifurcation and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments will typically be closer to the coupon interest rate when applying the guidance in Topic 835, “Interest.” The Company now accounts for its 0.375% convertible senior notes due July 15, 2024 (the "2019 Notes") as a single liability measured at amortized cost. As a result, the adoption of ASU 2020-06 had a material impact on the Company's consolidated financial statements, resulting in adjustments of $ 39.1 million, $ 17.3 million and $ 27.6 million to the opening balances of additional paid-in capital, retained earnings and Convertible Senior Notes, net, respectively, on the Company's consolidated balance sheet as of January 1, 2022. Additionally, due to the adoption of ASU 2020-06, the Company reversed the remaining balance of the deferred tax liability of $ 6.4 million, which was initially recorded in connection with the 2019 Notes. See Note 13, “Convertible Senior Notes,” for more information, including our modified disclosures as required by ASU 2020-06 upon adoption. 3. Fair Value Measurements Cash, Cash Equivalents and Marketable Securities Held to Maturity The following table summarizes the Company's cash, cash equivalents and marketable securities held to maturity as of December 31, 2022: As of December 31, 2022 Amortized Costs Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value (Amounts in thousands) Cash and cash equivalents: Cash and money market funds $ 523,458 $ — $ — $ 523,458 Total cash and cash equivalents 523,458 — — 523,458 Marketable securities held to maturity: U.S. treasury bills - short-term 100,299 24 — 100,323 Total cash, cash equivalents and marketable securities $ 623,757 $ 24 $ — $ 623,781 During the fourth quarter of 2022, the Company purchased $ 100.0 million of 6-month U.S. treasury bills with the positive intent and ability to hold them until maturity. Therefore, the Company classified this investment as held to maturity and stated it at amortized cost on the consolidated balance sheet. There is no comparable investment as of December 31, 2021. The amortized cost and fair value of the Company's held to maturity securities by contractual maturity at December 31, 2022 are summarized below. There is no comparable investment as of December 31, 2021: December 31, 2022 Amortized Costs Estimated Fair Value Maturity of one year or less $ 100,299 $ 100,323 Total $ 100,299 $ 100,323 83 Fair Value Measured on a Recurring Basis Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 31, 2022 and 2021: As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 343,929 $ — $ — $ 343,929 Liabilities: Short-term contingent consideration $ — $ — $ 13,950 $ 13,950 Long-term contingent consideration $ — $ — $ 51,559 $ 51,559 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 460,936 $ — $ — $ 460,936 Liabilities: Long-term contingent consideration $ — $ — $ 94,238 $ 94,238 Contingent Consideration – Earnout On September 20, 2021, the Company completed the Avitide Acquisition. Avitide is a privately-held affinity ligand discovery and development company headquartered in Lebanon, New Hampshire. The transaction consisted of upfront payments of $ 150.0 million and up to an additional $ 125.0 million (undiscounted) in contingent consideration earnout payments made equally in cash and the Company's common stock over a three-year performance period beginning January 1, 2022 and ending December 31, 2024. See Note 4, "Acquisitions" below for additional information. During 2022, a change in market inputs and a shift in revenue and volume projections, due to the expected timing of achievement over the three-year performance period, resulted in a material change in amounts reported as of December 31, 2022 . A reconciliation of the change in fair value of contingent consideration – earnout is included in the following table (amounts in thousands): Balance at December 31, 2021 $ 94,238 Decrease in fair value of contingent consideration earnouts ( 28,729 ) Balance at December 31, 2022 $ 65,509 The recurring Level 3 fair value measurement of our contingent consideration – earnout that we expect to be required to settle, include the following significant unobservable inputs: Contingent Consideration Earnout Fair Value as of December 31, 2022 Valuation Technique Unobservable Input Range Weighted Average (1) Probability of Commercialization-based Monte Carlo Success 100 % 100 % payments $ 28,969 Simulation Earnout Discount Rate 5.4 %- 6.1 % 5.7 % Volatility 20.8 % 20.8 % Revenue and Volume- Monte Carlo Revenue & Volume based payments $ 36,540 Simulation Discount Rate 5.4 % 5.4 % Earnout Discount Rate 5.4 %- 6.1 % 5.7 % (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. 84 The Company estimates the fair value of the contingent consideration earnouts using a Monte Carlo simulation. Changes in the projected performance of the acquired business could result in a higher or lower contingent consideration obligation in the future. Fair Value Measured on a Nonrecurring Basis During 2022, there were no re-measurements to fair value of financial assets and liabilities that are measured at fair value on a nonrecurring basis. Convertible Senior Notes In July 2019, the Company issued $ 287.5 million aggregate principal amount of the 2019 Notes. Interest is payable semi-annually in arrears on January 15 and July 15 of each year. The 2019 Notes will mature on July 15, 2024, unless earlier converted or repurchased in accordance with their terms. At December 31, 2022, the carrying value of the 2019 Notes was $ 284.6 million, net of unamortized debt issuance costs and the fair value of the 2019 Notes was $ 452.0 million. At December 31, 2021 , prior to the adoption of ASU 2020-06, the carrying value of the 2019 Notes was $ 255.3 million, net of unamortized discount and unamortized issuance costs, and the fair value of the 2019 Notes was $ 678.5 million. The fair value of the 2019 Notes is a Level 1 valuation and was determined based on the most recent trade activity of the 2019 Notes as of December 31, 2022 and 2021. The 2019 Notes are discussed in more detail in Note 13, “Convertible Senior Notes,” to these consolidated financial statements. 4. Acquisitions 2021 Acquisitions BioFlex Solutions LLC and Newton T&M Corp. On November 29, 2021, the Company entered into an Equity Purchase Agreement with Bioflex, NTM and each of Ralph Meola and Jason Nisler, to acquire 100 % of the outstanding securities of Bioflex and NTM (collectively, the “NTM Acquisition”). The transaction closed on December 16, 2021. NTM, which is headquartered in Newton, New Jersey, is the parent company of BioFlex and focuses on manufacturing of products, while BioFlex, also headquartered in Newton, New Jersey, commercializes branded products to biotech customers. The NTM Acquisition complements and expands our filtration offering paths as the industry migrates to single-use flow paths solutions for monoclonal antibody ("mAb"), vaccine and cell and gene therapy ("C&GT") applications, with a focus on single-use fluid management components, including single-use clamps, adapters, end caps and hose assemblies. The NTM Acquisition streamlines and increases control over many components in our single-use supply chain which ultimately should drive reduced lead-times for Repligen customers in the coming years. Consideration Transferred The NTM Acquisition was accounted for as a purchase of businesses under ASC 805, “Business Combinations” and the Company engaged a third-party valuation firm to assist with the valuation of the business acquired. Under the terms of the Equity Purchase Agreement, all outstanding shares of capital stock of BioFlex were acquired for consideration with a value totaling $ 31.6 million, which includes $ 3.0 million deposited into an escrow against which the Company may make claims for indemnification. Under the acquisition method of accounting, the assets acquired and liabilities assumed of BioFlex were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired is $ 4.6 million, the fair value of the intangible assets acquired is $ 17.2 million, and the residual goodwill is $ 9.8 million. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred $ 3.0 million of transaction and integration costs associated with the NTM Acquisition from the date of acquisition to December 31, 2022 , with $ 2.7 million of transaction and integration costs incurred in 2022 and $ 0.3 million incurred in 2021. The transaction and integration costs are included in operating expenses in the consolidated statements of comprehensive income for the periods ended December 31, 2022 and 2021. 85 Fair Value of Net Assets Acquired The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the final valuation. The Company has made appropriate adjustments to the purchase price allocation during the measurement period, which ended December 16, 2022. The components and estimated allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 2,870 Accounts receivable 1,408 Inventory 741 Prepaid expenses and other current assets 126 Property and equipment 34 Operating lease right of use asset 1,034 Customer relationships 13,240 Developed technology 3,540 Trademark and tradename 310 Non-competition agreements 60 Goodwill 9,834 Long term deferred tax asset 81 Accounts payable ( 224 ) Accrued liabilities ( 450 ) Operating lease liability ( 1,030 ) Operating lease liability, long-term ( 3 ) Fair value of net assets acquired $ 31,571 During 2022, the Company recorded net working capital adjustments of approximately $ 0.3 million related to pre-acquisition liabilities, which are included in goodwill and accrued liabilities in the table above. Acquired Goodwill The goodwill of $ 9.8 million represents future economic benefits expected to arise from anticipated synergies from the integration of BioFlex and NTM into the Company. These synergies include certain operating efficiencies and strategic benefits projected to be achieved as a result of the NTM Acquisition. Substantially all of the goodwill recorded is expected to be deductible for income tax purposes. Intangible Assets The following table sets forth the components of the identified intangible assets associated with the NTM Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 10 years $ 13,240 Developed technology 11 years 3,540 Trademark and tradename 15 years 310 Non-competition agreements 3 years 60 $ 17,150 Avitide, Inc. On September 16, 2021, the Company entered into an Agreement and Plan of Merger and Reorganization (“Avitide Merger Agreement”) with Avalon Merger Sub, Inc., a Delaware corporation and a wholly owned direct subsidiary of the Company, Avalon Merger Sub LLC, a Delaware limited liability company and a wholly owned direct subsidiary of the Company, Avitide, a Delaware corporation, and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity 86 as the representative, agent and attorney-in-fact of Avitide's securityholders to purchase Avitide. The transaction closed on September 20, 2021, and on the terms set forth in the Avitide Merger Agreement. Avitide, which is headquartered in Lebanon, New Hampshire, offers diverse libraries and leading technology in affinity ligand discovery and development resulting in best-in-class ligand discovery and development lead-times. The acquisition gives the Company a new platform for affinity resin development, including C&GT, and advances and expands the Company’s proteins and chromatography franchises to address the unique purification needs of gene therapies and other emerging modalities. Consideration Transferred The Avitide Acquisition was accounted for as a purchase of a business under ASC 805, “Business Combinations” and the Company engaged a third-party valuation firm to assist with the valuation of the business acquired. Under the terms of the Avitide Merger Agreement, all outstanding shares of capital stock of Avitide were cancelled and converted into the right to receive merger consideration with a value totaling up to $ 275.0 million, which consisted of upfront payments in aggregate of $ 150.0 million ($ 149.4 million, net of cash acquired) and up to an additional $ 125.0 million (undiscounted) in contingent consideration earnout payments if certain performance targets are achieved. Total consideration paid also included $ 0.8 million deposited into an escrow account against which the Company may make claims for indemnification. The Avitide Acquisition was funded through payment of $ 75.0 million in cash, the issuance of 271,096 unregistered shares of the Company’s common stock totaling $ 83.0 million and contingent consideration with fair value of approximately $ 88.4 million. Under the acquisition method of accounting, the assets acquired and liabilities assumed of Avitide were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired is $ 2.1 million, fair value of the intangible assets acquired is $ 46.7 million, and the residual goodwill is $ 197.5 million. The Company has incurred $ 5.6 million of transaction and integration costs associated with the Avitide Acquisition from the date of acquisition to December 31, 2022, with $ 3.0 million of transaction and integration costs incurred in 2022 and $ 2.6 million in 2021. The transaction costs are included in operating expenses in the consolidated statements of comprehensive income for the periods ended December 31, 2022 and 2021. During 2022 and 2021, due to the change in market inputs and a shift in revenue and volume projections, due to the expected timing of achievement over the three-year performance period, the Company recorded contingent consideration adjustments of ($ 28.7 ) million and $ 5.9 million to the Company’s consolidated statement of comprehensive income in 2022 and 2021, respectively. See Note 3, "Fair Value Measurements" for additional information. The preparation of the valuation required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable. However, actual results may differ from these estimates. Total consideration transferred is as follows (amounts in thousands): Cash consideration $ 74,962 Equity consideration 82,968 Contingent consideration - earnout 88,373 Fair value of net assets acquired $ 246,303 Fair Value of Net Assets Acquired The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the final valuation of Avitide. The Company has made appropriate adjustments to the purchase price allocation during the measurement period, which ended on September 20, 2022. 87 The components and estimated allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 572 Accounts receivable 228 Inventory 332 Prepaid expenses and other current assets 114 Property and equipment 1,862 Operating lease right of use asset 3,648 Customer relationships 24,580 Developed technology 20,650 Trademark and tradename 1,210 Non-competition agreements 210 Goodwill 197,476 Long term deferred tax asset 1,525 Accounts payable ( 215 ) Accrued liabilities ( 2,183 ) Operating lease liability ( 698 ) Operating lease liability, long-term ( 2,950 ) Other liabilities ( 58 ) Fair value of net assets acquired $ 246,303 Acquired Goodwill The goodwill of $ 197.5 million represents future economic benefits expected to arise from anticipated synergies from the integration of Avitide. These synergies include certain cost savings, operating efficiencies and other strategic benefits projected to be achieved as a result of the Avitide Acquisition. Substantially all of the goodwill recorded is expected to be nondeductible for income tax purposes. During 2022, the Company recorded adjustments to goodwill of $ 1.8 million related to a change in estimated tax benefits associated with the net operating loss carryforward filed on the Avitide pre-acquisition tax return. The offset of these adjustments is included in long term deferred tax asset in the table above. Intangible Assets The following table sets forth the components of the identified intangible assets associated with the Avitide Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 13 years $ 24,580 Developed technology 15 years 20,650 Trademark and tradename 18 years 1,210 Non-competition agreements 3 years 210 $ 46,650 Polymem S.A. On June 22, 2021, the Company entered into a Stock Purchase Agreement with Polymem, a company organized under the laws of France, and Jean-Michel Espenan and Franc Saux, acting together jointly and severally as the representatives of the sellers pursuant to which Repligen acquired all of the outstanding common stock of Polymem for $ 47.0 million in cash. The transaction closed on July 1, 2021 (the “Polymem Acquisition.”). Polymem, which is headquartered in, Toulouse, France, is a manufacturer of hollow fiber ("HF") membranes, membrane modules and systems for industrial and bioprocessing applications. Polymem products will complement and expand the Company’s portfolio of HF systems and consumables. The acquisition substantially increases Repligen’s membrane and module manufacturing capacity and establishes a world-class center of excellence in Europe to address the accelerating global demand for these innovative products. 88 Consideration Transferred The Company accounted for the Polymem Acquisition as a purchase of a business under ASC 805 and the Company engaged a third-party valuation firm to assist with the valuation of the business acquired. Payment for the transaction was denominated in Euros but is reflected here in U.S. dollars for presentation purposes based on an exchange rate of 0.8437 as of July 1, 2021, the date of acquisition. Total consideration paid was $ 47.0 million, which included $ 4.3 million deposited into an escrow account against which the Company may make claims for indemnification. Under the acquisition method of accounting, the assets acquired and liabilities assumed of Polymem were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired is $ 2.2 million, the fair value of the intangible assets acquired is $ 9.1 million, and the residual goodwill is $ 35.7 million. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred $ 8.2 million of transaction and integration costs associated with the Polymem Acquisition from the date of acquisition to December 31, 2022, with $ 5.1 million incurred in 2022 and $ 3.1 million incurred from the date of acquisition to December 31, 2021. The transaction costs are included in operating expenses in the consolidated statements of comprehensive income for the periods ended December 31, 2022 and 2021. Fair Value of Net Assets Acquired The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the final valuation of Polymem. The Company has made appropriate adjustments to the purchase price allocation during the measurement period, which ended on July 1, 2022. The components and final allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 353 Net working capital (excluding cash and inventory step-up) 414 Inventory step-up 543 Operating lease right of use assets 1,424 Property and equipment 3,145 Other assets 41 Developed technology 8,274 Trademark and tradenames 510 Non-compete agreements 312 Goodwill 35,680 Operating lease liability ( 1,253 ) Long term deferred tax liability ( 2,327 ) Other long-term liabilities ( 143 ) Fair value of net assets acquired $ 46,973 Acquired Goodwill The goodwill of $ 35.7 million represents future economic benefits expected to arise from anticipated synergies from the integration of Polymem. These synergies include certain operating efficiencies and strategic benefits projected to be achieved as a result of the Polymem Acquisition. Substantially all of the goodwill recorded is expected to be nondeductible for income tax purposes. 89 Intangible Assets The following table sets forth the components of the identified intangible assets associated with the Polymem Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Developed technology 13 years $ 8,274 Trademark and tradename 14 years 510 Non-competition agreements 5 years 312 $ 9,096 2020 Acquisitions ARTeSYN Biosolutions Holdings Ireland Limited On October 27, 2020, the Company entered into an Equity and Asset Purchase Agreement with ARTeSYN, a company organized under the laws of Ireland, Third Creek Holdings, LLC, a Nevada limited liability company, Alphinity, LLC, a Nevada limited liability company (“Alphinity”, and together with Third Creek Holdings, LLC the “Sellers”), and Michael Gagne, solely in his capacity as the representative of the Sellers, pursuant to which the Company acquired (i) all of the outstanding equity securities of ARTeSYN and (ii) certain assets from Alphinity related to the business of ARTeSYN (collectively, the “ARTeSYN Acquisition”) for approximately $ 200 million, comprised of approximately $ 130 million in cash to the Sellers and approximately $ 70 million in Repligen common stock to Third Creek. The transaction closed on December 3, 2020. ARTeSYN is headquartered in Waterford, Ireland and conducts its operations in Ireland, the United States and Estonia. Its suite of single-use solutions has been created with the goal of enabling “abundance in medicine” by allowing 10x greater efficiency in biologics manufacturing. The ARTeSYN team has created a number of solutions targeting the single-use space from single-use valves with fully disposable valve liners, XO ® skeletal supports, a hybrid small parts offering for de-bottlenecking traditional facilities, and fully automated SU process systems that have quickly become leading solutions in the bioprocessing industry. In addition to its single-use solutions, ARTeSYN also engages in the manufacture of large-scale systems to be used for biologics manufacturing. ARTeSYN has established downstream processing leadership with a suite of state of the art single-use systems for chromatography, filtration, continuous manufacturing and media/buffer prep workflows. In addition, the Company has integrated unique flow path assemblies utilizing the Company’s silicone extrusion and molding technology, to deliver highly differentiated, low hold-up volume systems that minimize product loss during processing. The ARTeSYN portfolio expands on the market success of the Company’s HF systems and complements its chromatography and tangential flow filtration ("TFF") product lines. Acquisition related costs are not included as a component of consideration transferred but are expensed in the periods in which the costs are incurred. The Company incurred $ 4.0 million in transaction and integration costs associated with the ARTeSYN Acquisition from the date of acquisition to December 31, 2020, and an additional $ 4.7 million of transaction and integration costs during 2021. The transaction costs are included in operating expenses in the consolidated statements of comprehensive income for the period ended December 31, 2021. Fair Value of Net Assets Acquired The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the preliminary valuation. We have made appropriate adjustments to the purchase price allocation during the measurement period, which ended on December 3, 2021. 90 During 2021, the Company recorded net working capital adjustments of $ 0.1 million related to settlement of pre-acquisition liabilities, which offset goodwill in the table below. The components and estimated allocation of the purchase price consists of the following amounts (amounts in thousands): Cash and cash equivalents $ 2,982 Accounts receivable 4,811 Inventory 8,592 Prepaid expenses and other current assets 5,561 Property and equipment 1,836 Operating lease right of use asset 1,611 Other noncurrent assets 26 Customer relationships 38,400 Developed technology 27,060 Trademark and tradename 1,630 Non-competition agreements 300 Goodwill 128,598 Accounts payable ( 2,251 ) Accrued liabilities ( 8,706 ) Deferred revenue ( 3,583 ) Deferred tax liabilities, net ( 1,240 ) Notes payable ( 24 ) Operating lease liability ( 417 ) Operating lease liability, long-term ( 1,193 ) Fair value of net assets acquired $ 203,993 Acquired Goodwill The goodwill of $ 128.6 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. Substantially all of the goodwill recorded is expected to be deductible for income tax purposes. Non-Metallic Solutions, Inc. On October 15, 2020, the Company entered into a Stock Purchase Agreement with Non-Metallic Solutions, Inc. ("NMS"), a Massachusetts corporation, and each of William Malloneé and Derek Masser, the legal and beneficial owners of NMS, to purchase NMS, which transaction subsequently closed on October 20, 2020 (the “NMS Acquisition”). NMS, headquartered in Auburn, Massachusetts, is a manufacturer of fabricated plastics, custom containers, and related assemblies and components used in the manufacturing of biologic drugs. The acquisition of NMS allows Repligen to expand its line of single-use systems and associated integrated flow path assemblies and streamline the supply chain for current products, providing more flexibility to scale and expand the Company's single-use and systems portfolios. Fair Value of Net Assets Acquired The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the preliminary valuation. We have made appropriate adjustments to the purchase price allocation during the measurement period, which ended on October 20, 2021. 91 The components and allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 1,163 Accounts receivable 415 Inventory 334 Prepaid expenses and other current assets 13 Property and equipment 73 Operating lease right of use asset 194 Customer relationships 6,370 Developed technology 1,810 Trademark and tradename 190 Non-competition agreements 90 Goodwill 6,713 Deferred tax assets 24 Accounts payable ( 96 ) Accrued liabilities ( 999 ) Operating lease liability ( 136 ) Operating lease liability, long-term ( 59 ) Fair value of net assets acquired $ 16,099 Acquired Goodwill The goodwill of $ 6.7 million represents future economic benefits expected to arise from anticipated synergies from the integration of NMS. These synergies include certain cost savings, operating efficiencies and other strategic benefits projected to be achieved as a result of the NMS Acquisition. Substantially all of the goodwill recorded is expected to be deductible for income tax purposes. The Company has included the operating results of our 2021 acquisitions of Polymem, Avitide and NTM and the 2020 acquisitions of ARTeSYN, NMS and EMT in its consolidated statements of comprehensive income since their respective acquisition dates. The Company does not consider these acquisitions to be material to its consolidated statements of comprehensive income and therefore has not included pro forma results. Effective July 11, 2021, EMT was absorbed into the Company by way of “short-form” merger pursuant to New York and Delaware law, which did not require a vote of the Company’s shareholders. 5. Leases The Company is a lessee under leases of manufacturing facilities, office spaces, machinery, certain office equipment and vehicles. A majority of the Company’s leases are operating leases with remaining lease terms between one month and 14 years. Finance leases are immaterial to the Company’s consolidated financial statements. The Company determines if an arrangement qualifies as a lease and what type of lease it is at inception. The Company elected the package of practical expedients permitted under the transition guidance within the new lease standard, which among other things, allowed it to continue to account for existing leases based on the historical lease classification. The Company also elected the practical expedients to combine lease and non-lease components and to exclude right of use assets and lease liabilities for leases with an initial term of 12 months or less from the balance sheet. Some of the lease agreements the Company enters into include Company options to either extend and/or early terminate the lease, the costs of which are included in the Company’s operating lease liabilities to the extent that such options are reasonably certain of being exercised. Leases with renewal options allow the Company to extend the lease term typically between 1 and 5 years per option, some of its leases have multiple options to extend. When determining if a renewal option is reasonably certain of being exercised, the Company considers several economic factors, including but not limited to, the significance of leasehold improvements incurred on the property, whether the asset is difficult to replace, underlying contractual obligations, or specific characteristics unique to that particular lease that would make it reasonably certain that the Company would exercise such options. 92 As of December 31, 2022 and 2021, operating lease right of use assets wer e $ 125.0 million and $ 101.6 million, respectively and operating lease liabilities were $ 138.3 million and $ 110.8 million, respectively. The Company signed the Sixth Amendment of Lease for our headquarters in Waltham, Massachusetts in September 2021 to expand the facility by 74,108 square feet. The facility expanded by 21,244 square feet immediately. The remaining 52,864 square feet commenced in June 2022. As a result of this and the expansion of facilities in Bridgewater, New Jersey and Clifton Park, New York, the operating right of use asset and operating lease liability balances increased by a total of $ 23.5 million in 2022, net of the normal amortization of existing leases. The maturities of the Company’s operating lease liabilities as of December 31, 2022 are as follows (amounts in thousands): As of December 31, 2022 Amount 2023 $ 19,936 2024 21,651 2025 21,566 2026 21,367 2027 20,194 2028 and thereafter 78,312 Total future minimum lease payments 183,026 Less lease incentives ( 14,822 ) Less amount of lease payment representing interest ( 29,858 ) Total operating lease liabilities $ 138,346 Total operating lease liabilities included on the Company’s consolidated balance sheet are as follows (amounts in thousands): December 31, 2022 2021 Operating lease liability $ 6,957 $ 8,303 Operating lease liability, long-term 131,389 102,492 Minimum operating lease payments $ 138,346 $ 110,795 Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments recognized in the period those payments are incurred. For the year ended December 31, 2022 and 2021, total lease cost is comprised of the following: For the Years Ended December 31, Lease Cost 2022 2021 (Amounts in thousands) Operating lease cost $ 17,833 $ 9,838 Variable operating lease cost 11,317 7,118 Lease cost $ 29,150 $ 16,956 The following information represents supplemental disclosure for the consolidated statements of cash flows related to operating leases (amounts in thousands): For the Years Ended December 31, 2022 2021 Operating lease cost $ ( 13,757 ) $ ( 8,863 ) Most of the leases do not provide implicit interest rates and therefore the Company determines the discount rate based on its incremental borrowing rate. The incremental borrowing rate for the Company’s leases is determined based on lease term and currency in which the lease payments are made. 93 The weighted average remaining lease term and the weighted average discount rate used to measure the Company’s operating lease liabilities as of December 31, 2022, were: Weighted average remaining lease term (years) 8.60 Weighted average discount rate 4.08 % 6. Revenue Recognition The Company generates revenue from the sale of bioprocessing products, equipment devices, and related consumables used with these equipment devices to customers in the life science and biopharmaceutical industries. Under ASC 606, “Revenue from Contracts with Customers,” revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Disaggregation of Revenue Revenue for the years ended December 31, 2022, 2021 and 2020 was as follows: For the Years Ended December 31, 2022 2021 2020 (Amounts in thousands) Product revenue $ 801,183 $ 670,319 $ 366,136 Royalty and other income 353 215 124 Total revenue $ 801,536 $ 670,534 $ 366,260 When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because all of its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. In addition, a significant portion of the Company’s revenues are generated from a few customers; therefore, economic factors specific to these customers could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Disaggregated revenue from contracts with customers by geographic region can be found in Note 2, “Summary of Significant Accounting Policies – Segment Reporting,” above. There was no revenue from customers that represented 10 % or more of the Company's total revenue for the year ended December 31, 2022. Revenue from Pfizer Inc. was $ 68.3 million, or 10 %, of the Company's total revenue for the year ended December 31, 2021 and MilliporeSigma accounted for $ 39.5 million, or 11 % of total revenues in the year ended December 31, 2020. Filtration Products The Company’s filtration products generate revenue through the sale of KrosFlo hollow fiber ("HF") TFF systems, TangenX ® flat sheet ("FS") cassettes, Spectrum ® HF filters, membranes and modules, XCell ATF systems and related consumables. Supporting our systems, we also sell ProConnex ® Flow Path assemblies and custom silicone-based, single-use flow path assemblies and components from Polymem, BioFlex, NMS and ARTeSYN, four acquisitions completed in 2021 and 2020. The Company’s KrosFlo systems are used in the filtration, isolation, purification and concentration of biologics and diagnostic products. TFF is a rapid and efficient method for separation and purification of biomolecules that is widely used in laboratory, process development and process scale applications in biopharmaceutical manufacturing. Sales of large-scale systems generally include components and consumables as well as training and installation services at the request of the customer. Because the initial sale of components and consumables is necessary for the operation of the system, such items are combined with the systems as a single performance obligation. Training and installation services do not significantly modify or customize these systems and therefore represent a distinct performance obligation. 94 The Company’s TangenX FS cassettes (SIUS, SIUS Gamma ® and PRO) are not highly interdependent on one another and are therefore considered distinct products that represent separate performance obligations. Product revenue from the sale of TangenX FS cassettes is generally recognized at a point in time upon transfer of control of the customer. The Company’s other filtration product offerings are not highly interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Revenue on these products is generally recognized at a point in time upon transfer of control to the customer. The Company invoices the customer for the installation and training services in an amount that directly corresponds with the value to the customer of the Company’s performance to date; therefore, revenue recognized is based on the amount billable to the customer in accordance with the practical expedient under ASC 606-10-55-18. The Company also markets the XCell ATF system, a technologically advanced filtration device used in upstream processes to continuously remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest. XCell ATF systems typically include a filtration system and consumables (i.e., tubing sets, metal stands) as well as training and installation services at the request of the customer. The filtration system and consumables are considered distinct products and therefore represent separate performance obligations. First time purchasers of the systems typically purchase a controller that is shipped with the tubing set(s) and metal stand(s). The controller is not considered distinct as it is a proprietary product that is highly interdependent with the filtration system; therefore, the controller is combined with the filtration system and accounted for as a single performance obligation. The training and installation services do not significantly modify or customize the XCell ATF system and therefore represent a distinct performance obligation. XCell ATF system product revenue related to the filtration system (including the controller if applicable) and consumables is generally recognized at a point in time upon transfer of control to the customer. XCell ATF system service revenue related to training and installation services is generally recognized over time, as the customer simultaneously receives and consumes the benefits as the Company performs. The Company invoices the customer for the installation and training services in an amount that directly corresponds with the value to the customer of the Company’s performance to date; therefore, revenue recognized is based on the amount billable to the customer in accordance with the practical expedient under ASC 606-10-55-18. Chromatography Products The Company’s chromatography products include a number of products used in the downstream purification and quality control of biological drugs. The majority of chromatography revenue relates to the OPUS pre-packed chromatography column line. OPUS columns are designed to be disposable following a production campaign. Each OPUS column is delivered pre-packaged with the customer’s choice of chromatography resin, which is either provided by the Company for the customer or customer supplied. In either scenario, the OPUS column and resin are not interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Chromatography product revenue is generally recognized at a point in time upon transfer of control to the customer. Process Analytics Products The process analytics franchise generates revenue primarily through the sale of the SoloVPE, FlowVPE and FlowVPX slope spectroscopy systems, consumables and service. These products complement and support the Company’s existing filtration, chromatography and proteins franchises as they allow end-users to make in-line protein concentration measurements in filtration, chromatography and fill-finish applications, designed to allow for real-time process monitoring. Process analytics product revenue is generally recognized at a point in time upon transfer of control to the customer. Protein Products The Company’s protein franchise generates revenue through the sale of Protein A affinity ligands and growth factors. Protein A ligands are an essential component of Protein A chromatography resins (media) used in the purification of virtually all mAb-based drugs on the market or in development. The Company manufactures multiple forms of Protein A ligands under long-term supply agreements with major life sciences companies, who in turn sell their Protein A chromatography media to end users (biopharmaceutical manufacturers). The Company also manufactures growth factors for sale under long-term supply agreements with certain life sciences companies as well as for direct sales to its customers. Each protein product is considered distinct and therefore represents a separate performance obligation. Protein product revenue is generally recognized at a point in time upon transfer of control to the customer. 95 On September 20, 2021, the Company completed the Avitide Acquisition and added its diverse libraries and leading technology in affinity ligand discovery and development to its proteins franchise. The acquisition gives the Company a new platform for affinity resin development, including C&GT, and advances and expands the Company’s proteins and chromatography franchises to address the unique purification needs of gene therapies and other emerging modalities. Other Products The Company’s other products include operating room products sold to hospitals. Other product revenue is generally recognized at a point in time upon transfer of control to the customer. Transaction Price Allocated to Future Performance Obligations Remaining performance obligations represent the transaction price of contracts for which work has not been performed or has been partially performed. The Company’s future performance obligations relate primarily to the installation and training of certain of its systems sold to customers. These performance obligations are completed within one year of receipt of a purchase order from its customers. Accordingly, the Company has elected to not disclose the value of these unsatisfied performance obligations as provided under ASC 606-10-50-14. Contract Balances from Contracts with Customers The following table provides information about receivables and deferred revenue from contracts with customers as of December 31, 2022 (amounts in thousands): December 31, December 31, 2022 2021 Balances from contracts with customers only: Accounts receivable $ 116,247 $ 117,420 Deferred revenue (included in accrued liabilities and other noncurrent liabilities in the consolidated balance sheets) $ 19,631 $ 14,797 Revenue recognized during periods presented relating to: The beginning deferred revenue balance $ 13,390 $ 13,708 The timing of revenue recognition, billings and cash collections results in the accounts receivable and deferred revenue balances on the Company’s consolidated balance sheets. A contract asset is created when the Company satisfies a performance obligation by transferring a promised good to the customer. Contract assets may represent conditional or unconditional rights to consideration. The right is conditional and recorded as a contract asset if the Company must first satisfy another performance obligation in the contract before it is entitled to payment from the customer. Contract assets are transferred to billed receivables once the right becomes unconditional. If the Company has the unconditional right to receive consideration from the customer, the contract asset is accounted for as a billed receivable and presented separately from other contract assets. A right is unconditional if nothing other than the passage of time is required before payment of that consideration is due. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. Costs to Obtain or Fulfill a Customer Contract The Company’s sales commission structure is based on achieving revenue targets. The commissions are driven by revenue derived from customer purchase orders which are short term in nature. 96 Applying the practical expedient in paragraph 340-40-25-4, the Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses in our consolidated statement of comprehensive income. When shipping and handling costs are incurred after a customer obtains control of the products, the Company accounts for these as costs to fulfill the promise and not as a separate performance obligation. 7. Credit Losses Effective January 1, 2020, the Company adopted ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” prospectively. ASU 2016-13 replaces the incurred loss impairment model with an expected credit loss impairment model for financial instruments, including trade receivables. The guidance requires entities to consider forward-looking information to estimate expected credit losses, resulting in earlier recognition of losses for receivables that are current or not yet due. Upon adoption, changes in the allowance were not material for the transition period starting January 1, 2020 through December 31, 2020. The Company is exposed to credit losses primarily through sales of products and services. The Company’s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions and a review of the current status of customers' trade accounts receivable. Customers are pooled based on sharing specific risk factors, including geographic location. Due to the short-term nature of such receivables, the estimated accounts receivable that may not be collected is based on aging of the accounts receivable balances. Customers are assessed for credit worthiness upfront through a credit review, which includes assessment based on the Company’s analysis of their financial statements when a credit rating is not available. The Company evaluates contract terms and conditions, country and political risk, and may require prepayment to mitigate risk of loss. Specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. The Company monitors changes to the receivables balance on a timely basis, and balances are written off as they are determined to be uncollectable after all collection efforts have been exhausted. Estimates of potential credit losses are used to determine the allowance. It is based on assessment of anticipated payment and all other historical, current and future information that is reasonably available. The accounts receivable balance on the Company’s consolidated balance sheet as of December 31, 2022 was $ 116.2 million, net o f $ 1.4 million of allowances. The following table provides a roll-forward of the allowance for credit losses in 2022 that is deducted from the amortized cost basis of accounts receivable to present the net amount expected to be collected (amounts in thousands): For the Years Ended December 31, 2022 2021 Balance of allowance for credit losses, beginning of period $ ( 1,417 ) $ ( 762 ) Current period change for write-offs 126 173 Current period change for expected credit losses ( 74 ) ( 828 ) Balance of allowance for credit losses, end of period $ ( 1,365 ) $ ( 1,417 ) 8. Goodwill and Intangible Assets Goodwill Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination and determined to have an indefinite useful life is not amortized, 97 but instead is tested for impairment at least annually in accordance with ASC 350. The following table represents the changes in the carrying value of goodwill for the years ended December 31, 2022 and 2021 (amounts in thousands): Balance as of December 31, 2020 $ 618,305 Measurement period adjustment - NMS ( 71 ) Measurement period adjustment - ARTeSYN ( 60 ) Acquisition of Polymem 35,680 Acquisition of Avitide 199,245 Acquisition of NTM 10,180 Cumulative translation adjustment ( 2,917 ) Balance as of December 31, 2021 $ 860,362 Measurement period adjustment - BioFlex ( 346 ) Measurement period adjustment - Avitide ( 1,768 ) Cumulative translation adjustment ( 2,735 ) Balance as of December 31, 2022 $ 855,513 During each of the fourth quarters of 2022, 2021 and 2020, the Company completed its annual impairment assessments and concluded that goodwill was not impaired in any of those years. Intangible Assets Intangible assets with a definitive life are amortized over their useful lives using the straight-line method, and the amortization expense is recorded within cost of product revenue and selling, general and administrative expense in the Company’s consolidated statements of comprehensive income. Intangible assets and their related useful lives are reviewed at least annually to determine if any adverse conditions existed that would indicate the carrying value of these assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for the Company’s products or changes in the size of the market for the Company’s products. If impairment indicators are present, the Company determines whether the underlying intangible asset is recoverable through estimated future undiscounted cash flows. If the asset is not found to be recoverable, it is written down to the estimated fair value of the asset based on the sum of the future discounted cash flows expected to result from the use and disposition of the asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. The Company continues to believe that its definite-lived intangible assets are recoverable at December 31, 2022. Indefinite-lived intangible assets are tested for impairment at least annually. There has been no impairment of our intangible assets for the periods presented. Intangible assets, net consisted of the following at December 31, 2022: December 31, 2022 Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) (Amounts in thousands) Finite-lived intangible assets: Technology - developed (1) $ 190,463 $ ( 30,992 ) $ 159,471 16 Patents 240 ( 240 ) — 8 Customer relationships 252,934 ( 66,559 ) 186,375 15 Trademarks 7,682 ( 1,319 ) 6,363 19 Other intangibles 2,811 ( 2,044 ) 767 4 Total finite-lived intangible assets 454,130 ( 101,154 ) 352,976 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 454,830 $ ( 101,154 ) $ 353,676 98 (1) Includes an upfront payment paid to DRS Daylight Solutions, Inc. ("Daylight") in September 2022 to exclusively license and commercialization rights to use certain technology and intellectual property which Daylight owns. The expected useful life of this technology is 15 years, which is the term of the exclusive License Agreement ("Daylight Agreement") and the period the Company expects to be able to utilize the license and which the technology will contribute directly to cash flows. See Note 12, "Commitments and Contingencies" for more information on this transaction. Intangible assets consisted of the following at December 31, 2021: December 31, 2021 Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 146,097 $ ( 21,553 ) $ 124,544 17 Patents 240 ( 240 ) — 8 Customer relationships 254,699 ( 50,719 ) 203,980 15 Trademarks 7,699 ( 877 ) 6,822 19 Other intangibles 2,839 ( 1,611 ) 1,228 4 Total finite-lived intangible assets 411,574 ( 75,000 ) 336,574 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 412,274 $ ( 75,000 ) $ 337,274 Amortization expense for finite-lived intangible assets was $ 27.1 million, $ 22.1 million and $ 16.1 million for the years ended December 31, 2022, 2021 and 2020 , respectively. As of December 31, 2022, the Company expects to record the following amortization expense (amounts in thousands): Estimated Amortization For the Years Ended December 31, Expense 2023 $ 29,286 2024 28,699 2025 28,361 2026 28,333 2027 28,305 2028 and thereafter 209,992 Total $ 352,976 9. Consolidated Balance Sheet Detail Inventories, net Inventories, net consists of the following: December 31, 2022 2021 (Amounts in thousands) Raw materials $ 149,438 $ 123,321 Work-in-process 6,183 8,119 Finished products 82,656 53,054 Total inventories, net $ 238,277 $ 184,494 99 Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following: December 31, 2022 2021 (Amounts in thousands) Equipment maintenance and services $ 7,135 $ 10,857 Prepaid income taxes 519 3,970 Prepaid insurance 1,909 2,713 Other 10,274 8,409 Total prepaid expenses and other current assets $ 19,837 $ 25,949 Property, Plant and Equipment Property, plant and equipment consist of the following: December 31, 2022 2021 (Amounts in thousands) Land $ 1,003 $ 1,023 Buildings 1,599 764 Leasehold improvements 115,672 52,505 Equipment 94,613 70,983 Furniture, fixtures and office equipment 8,307 9,137 Computer hardware and software 29,813 22,380 Construction in progress 31,553 38,446 Other 420 443 Total property, plant and equipment 282,980 195,681 Less - Accumulated depreciation ( 92,307 ) ( 70,717 ) Total property, plant and equipment, net $ 190,673 $ 124,964 Depreciation expense totaled $ 23.9 million, $ 16.4 million and $ 10.9 million in the fiscal years ended December 31, 2022, 2021 and 2020, respectively. Accrued Liabilities Accrued liabilities consist of the following: December 31, 2022 2021 (Amounts in thousands) Employee compensation $ 33,522 $ 42,147 Deferred revenue 19,283 14,675 Income taxes payable 2,459 4,984 Other 15,856 13,692 Total accrued liabilities $ 71,120 $ 75,498 10. Income Taxes The components of income before income taxes are as follows: For the Years Ended December 31, 2022 2021 2020 (Amounts in thousands) Domestic $ 153,446 $ 81,984 $ 27,545 Foreign 65,694 71,559 31,672 Income before income taxes $ 219,140 $ 153,543 $ 59,217 100 The components of the income tax provision are as follows: For the Years Ended December 31, 2022 2021 2020 (Amounts in thousands) Components of the income tax provision (benefit): Current $ 34,800 $ 20,166 $ 5,193 Deferred ( 1,619 ) 5,086 ( 5,902 ) Total $ 33,181 $ 25,252 $ ( 709 ) Jurisdictional components of the income tax provision (benefit): Federal $ 17,662 $ 8,321 $ ( 4,741 ) State 1,381 1,251 ( 3,011 ) Foreign 14,138 15,680 7,043 Total $ 33,181 $ 25,252 $ ( 709 ) At December 31, 2022 , the Company had federal net operating loss carryforwards of $ 42.9 million, state net operating loss carryforwards of $ 0.8 million, and foreign net operating loss carryforwards of $ 4.9 million. Federal net operating loss carryforwards of $ 7.3 million will expire at various dates through 2037 . The state net operating loss carryforwards will expire at various dates through 2041, while the foreign net operating loss carryforwards do not expire. The other $ 35.6 million of federal net operating loss carryforwards have unlimited carryforward periods. At December 31, 2022 , the Company had state business tax credits carryforwards of $ 3.8 million available to reduce future domestic income taxes. The business tax credit carryforwards will expire at various dates through 2042. The net operating loss and business tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may be limited in the event of certain changes in the ownership interest of significant shareholders. The components of deferred income taxes are as follows: December 31, 2022 2021 (Amounts in thousands) Deferred tax assets: Stock-based compensation expense $ 5,323 $ 5,144 Operating leases 31,564 26,264 Capitalized research and development 9,102 — Inventory 5,983 3,082 Net operating loss carryforwards 9,808 10,841 Business tax credit carryforwards 2,639 1,834 Other 4,440 3,504 Total deferred tax assets 68,859 50,669 Less: valuation allowance ( 19 ) ( 718 ) Net deferred tax assets 68,840 49,951 Deferred tax liabilities: Fixed assets ( 18,965 ) ( 7,779 ) Acquired intangible assets ( 43,549 ) ( 43,227 ) Operating lease right of use assets ( 28,486 ) ( 24,114 ) Conversion option on convertible notes — ( 6,408 ) Total deferred tax liabilities ( 91,000 ) ( 81,528 ) Total net deferred tax liabilities $ ( 22,160 ) $ ( 31,577 ) The net change in the total valuation allowance for the year ended December 31, 2022 and 2021 was a decrease of approximately $ 0.7 million and a decrease of $ 9,000 , respectively. 101 The reconciliation of the federal statutory rate to the effective income tax rate for the years ended December 31, 2022, 2021 and 2020 is as follows: For the Years Ended December 31, 2022 2022 2021 2020 Amount % Amount % Amount % (Amounts in thousands, except percentages) Income before income taxes $ 219,140 $ 153,543 $ 59,217 Expected tax at statutory rate 46,020 21.0 % 32,247 21.0 % 12,436 21.0 % Adjustments due to: Difference between U.S. and foreign tax 1,024 0.5 % 530 0.3 % 618 1.0 % State income and franchise tax 3,509 1.6 % 1,462 1.0 % 133 0.2 % Business tax credits ( 5,139 ) ( 2.3 %) ( 2,239 ) ( 1.5 %) ( 4,660 ) ( 7.9 %) Stock-based compensation expense ( 5,638 ) ( 2.6 %) ( 9,049 ) ( 5.9 %) ( 9,243 ) ( 15.6 %) U.S. taxation of foreign earnings 83 0.0 % 30 0.0 % 51 0.1 % Foreign-derived intangible income ( 5,042 ) ( 2.3 %) ( 2,547 ) ( 1.7 %) — 0.0 % Executive compensation 5,441 2.5 % 3,397 2.2 % 1,401 2.4 % Contingent consideration ( 6,033 ) ( 2.8 %) 1,232 0.8 % — 0.0 % Change in U.S. and foreign tax rates 2 0.0 % 32 0.0 % ( 2,650 ) ( 4.5 %) Uncertain tax provisions 234 0.1 % ( 443 ) ( 0.3 %) ( 168 ) ( 0.3 %) Change in valuation allowance ( 688 ) ( 0.3 %) ( 48 ) ( 0.0 %) ( 12 ) ( 0.0 %) Other ( 592 ) ( 0.3 %) 648 0.4 % 1,385 2.3 % Income tax provision $ 33,181 15.1 % $ 25,252 16.4 % $ ( 709 ) ( 1.2 %) The Company’s tax returns are subject to examination by federal, state and foreign tax authorities. The Company’s two major tax jurisdictions are subject to examination for the following periods: Jurisdiction Fiscal Years Subject to Examination United States - federal and state 2018 - 2022 Sweden 2017 - 2022 The following is a tabular reconciliation of the total amounts of unrecognized tax benefits: For the Years Ended December 31, 2022 2022 2021 (Amounts in thousands) Balance of gross unrecognized tax benefits, beginning of period $ 2,786 $ 3,200 Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken in the current period 146 133 Gross amounts of increases and (decreases) in unrecognized tax benefits as a result of tax positions taken in the prior period 64 ( 500 ) Gross amounts of decreases due to release — ( 47 ) Balance of gross unrecognized tax benefits, end of period $ 2,996 $ 2,786 Included in the balance of unrecognized tax benefits as of December 31, 2022 , are $ 3.0 million of tax benefits that, if recognized, would affect the effective tax rate. The Company classifies interest and penalties related to income taxes as components of its income tax provision. In 2022, a net expense of approximately $ 24,000 was recorded to the income tax provision related to interest and penalties while in 2021 and 2020, net (benefit)/expenses of approximately ($ 29,000 ) and $ 17,000 , respectively, were recorded. The amount of interest and penalties recorded in the accompanying consolidated balance sheets was approximately $ 52,000 and $ 29,000 as of December 31, 2022 and 2021, respectively. The Company does not anticipate the amount of unrecognized tax benefits to change over the next twelve months. On August 16, 2022, the United States enacted the Inflation Reduction Act of 2022 ("IRA"), which, among other things, implements a 15 % alternative minimum tax on global adjusted financial statement income of certain large corporations, a 1 % excise tax on net stock repurchases and several tax incentives to promote clean energy and will become effective beginning in 102 2023. The Company evaluated the provisions of the IRA and no provision had, or will have a material effect on our consolidated financial position or results of operations as of December 31, 2022. As of December 31, 2022 , the Company has accumulated undistributed earnings generated by its foreign subsidiaries of approximately $ 148.2 million. Because $ 5.7 million of such earnings have previously been subject to the one-time transition tax on foreign earnings required by the Tax Cuts and Jobs Act enacted in December 2017, any additional taxes due with respect to such earnings or the excess of the amount for financial reporting over the tax basis of our foreign investments would generally be limited to foreign and state taxes. At December 31, 2022 , the Company has not provided for taxes on outside basis differences of its foreign subsidiaries as it is not practicable and the Company has the ability and intent to indefinitely reinvest the undistributed earnings of its foreign subsidiaries, and there are no needs for such earnings in the United States that would contradict its plan to indefinitely reinvest. 11. Stockholders’ Equity Public Offerings of Common Stock On December 8, 2020, the Company completed a public offering in which 1,725,000 shares of its common stock, including the underwriters’ exercise in full of an option to purchase an additional 225,000 shares, were sold to the public at a price of $ 181.00 per share (the “December Stock Offering”). The net proceeds of the December Stock Offering, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company, were approximately $ 297.8 million. On July 19, 2019, the Company completed a public offering in which 1,587,000 shares of its common stock, including the underwriters’ exercise in full of an option to purchase an additional 207,000 shares, were sold to the public at a price of $ 87.00 per share (the “July Stock Offering”). The net proceeds of the July Stock Offering, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company, were approximately $ 131.1 million. On May 3, 2019, the Company completed a public offering in which 3,144,531 shares of its common stock, including the underwriters’ full exercise of an option to purchase up to an additional 410,156 shares, were sold to the public at a price of $ 64.00 per share (the "May Stock Offering"). The total proceeds received by the Company from the May Stock Offering, net of underwriting discounts and commissions and other estimated offering expenses payable by the Company, totaled approximately $ 189.6 million. Stock Option and Incentive Plans At the Company’s 2018 Annual Meeting of Stockholders held on May 16, 2018, the Company’s shareholders approved the 2018 Stock Option and Incentive Plan (the “2018 Plan”). Under the 2018 Plan the number of shares of the Company’s common stock that are reserved and available for issuance shall be 2,778,000 plus the number of shares of common stock available for issuance under the Company’s Amended and Restated 2012 Stock Option and Incentive Plan (the “2012 Plan”). The shares of common stock underlying any awards under the 2018 Plan, 2012 Plan and the Second Amended and Restated 2001 Repligen Corporation Stock Plan (the “2001 Plan,” and together with the 2018 Plan and 2012 Plan, the “Plans”) that are forfeited, canceled or otherwise terminated (other than by exercise) shall be added back to the shares of stock available for issuance under the 2018 Plan. At December 31, 2022, 1,904,702 shares were available for future grants under the 2018 Plan. Stock-Based Compensation The Company recorded stock-based compensation expense of $ 27.3 million, $ 27.5 million and $ 17.0 million for the years ended December 31, 2022, 2021 and 2020 , respectively, for share-based awards granted under the Plans. The following table presents stock-based compensation expense in the Company’s consolidated statements of comprehensive income: For the Years Ended December 31, 2022 2021 2020 (Amounts in thousands) Cost of product revenue $ 2,525 $ 2,021 $ 1,929 Research and development 2,622 2,856 1,534 Selling, general and administrative 22,169 22,623 13,544 Total stock-based compensation $ 27,316 $ 27,500 $ 17,007 103 The 2018 Plan allows for the granting of incentive and nonqualified options to purchase shares of common stock, restricted stock and other equity awards. Except for the grant to the Company’s Chief Executive Officer (“CEO”) in 2018 mentioned below, employee grants under the Plans generally vest over a three - to five-year period, with 20 %- 33 % vesting on the first anniversary of the date of grant and the remainder vesting in equal yearly installments thereafter. Nonqualified options issued to non-employee directors under the Plans generally vest over one year. In the first quarter of 2018, to create a longer-term retention incentive, the Company’s Compensation Committee granted long-term incentive compensation awards to its CEO which consisted of both stock options and restricted stock units that are subject to time-based vesting over nine years . Options granted under the Plans have a maximum term of ten years from the date of grant and generally, the exercise price of the stock options equals the fair market value of the Company’s common stock on the date of grant. At December 31, 2022, options to purchase 609,965 shares and 531,034 stock units were outstanding under the Plans. Stock Options The Company uses the Black-Scholes option pricing model to calculate the fair value of stock option awards on the grant date, and measures stock-based compensation costs of stock options at the grant date based on the estimated fair value of the award. The Company recognizes expense on awards with service-based vesting over the employee’s requisite service period on a straight-line basis. The Company recognizes stock-based compensation expense for options that are ultimately expected to vest, and accordingly, such compensation expense has been adjusted for estimated forfeitures. The fair value of stock option awards granted during the years ended December 31, 2022, 2021 and 2020 were calculated using the following estimated assumptions: For the Years Ended December 31, 2022 2021 2020 Expected term (in years) 5.5 - 6.5 5.5 - 6.5 5.5 - 6.5 Expected volatility (range) 41.44 - 43.96 % 44.57 - 45.27 % 45.14 - 50.87 % Risk-free interest rate 1.86 - 4.07 % 0.77 - 1.07 % 0.34 - 1.15 % Expected dividend yield 0 % 0 % 0 % Information regarding option activity for the year ended December 31, 2022, under the Plans is summarized below: Shares Weighted average exercise price Weighted- Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value (in Thousands) Options outstanding at December 31, 2021 625,107 $ 54.15 Granted 87,838 $ 190.90 Exercised ( 86,980 ) $ 42.62 Forfeited/expired/cancelled ( 16,000 ) $ 196.79 Options outstanding at December 31, 2022 609,965 $ 71.74 Options exercisable at December 31, 2022 317,218 $ 47.93 Vested and expected to vest at December 31, 2022 (1) 594,350 $ 71.30 5.85 $ 61,155 (1) Represents the number of vested options as of December 31, 2022 plus the number of unvested options expected to vest as of December 31, 2022, based on the unvested outstanding options at December 31, 2022 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees. The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on December 31, 2022, the last business day of 2022, of $ 169.31 per share and the exercise price of 104 each in-the-money option) that would have been received by the option holders had all option holders exercised their options on December 31, 2022. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022, 2021 and 2020 was $ 14.1 million, $ 20.3 million and $ 36.6 million, respectively. The weighted average grant date fair value of options granted during the years ended December 31, 2022, 2021 and 2020 was $ 87.40 , $ 88.01 and $ 53.06 , respectively. The total fair value of stock options that vested during the years ended December 31, 2022, 2021 and 2020 was $ 3.1 million, $ 3.0 million and $ 2.8 million, respectively. Stock Units The fair value of stock units is calculated using the closing price of the Company’s common stock on the date of grant. The Company recognizes expense on awards with service-based vesting over the employee's requisite service period on a straight-line basis. Prior to 2020, the Company issued performance stock units to certain employees which are tied to the achievement of certain Company financial goal metrics and the passage of time. Since 2020, the Company has implemented formal programs that issue performance stock units to certain employees set to vest upon the achievement of individual goals and financial goals of the Company, as well as the passage of time. The Company recognizes expense on performance-based awards over the vesting period based on the probability that the performance metrics will be achieved. Information regarding stock unit activity, which includes activity for restricted stock units and performance stock units, for the year ended December 31, 2022 under the Plans is summarized below: Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2021 606,685 $ 115.11 Awarded 194,633 $ 191.61 Vested ( 208,531 ) $ 98.90 Forfeited/cancelled ( 61,753 ) $ 161.05 Unvested at December 31, 2022 531,034 $ 142.57 Vested and expected to vest at December 31, 2022 (1) 505,611 $ 138.17 (1) Represents the number of vested stock units as of December 31, 2022, plus the number of unvested stock units expected to vest as of December 31, 2022, based on the unvested outstanding stock units at December 31, 2022 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees. The aggregate intrinsic value of stock units vested during the years ended December 31, 2022, 2021 and 2020 was $ 43.9 million, $ 46.5 million and $ 28.3 million, respectively. The total fair value of stock units that vested during the years ended December 31, 2022, 2021 and 2020 was $ 22.7 million, $ 13.9 million and $ 10.85 million, respectively. As of December 31, 2022, there was $ 63.9 million of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 3.01 years. The Company expects 2,071,467 unvested options and stock units to vest over the next five years . 12. Commitments and Contingencies License Agreement On September 19, 2022, the Company entered into the Daylight Agreement with Daylight, giving the Company exclusive license and commercialization rights to use certain technology and intellectual property subject to conditions set forth in the Daylight Agreement. The Company agreed to pay Daylight (i) an initial, one-time, non-refundable, non-creditable upfront cash payment and (ii) certain quarterly royalty payments. Pursuant to the Daylight Agreement, the Company obtains the exclusive, non-transferrable, right and license to use specifically in the field of bioprocessing, the Daylight intellectual property called Culpeo ® QCL-IR Liquid Analyzer ("Culpeo"), which is a 105 compact, intelligent spectrometer that uses the power of quantum cascade lasers ("QCLs") to analyze and identify chemicals. Under the Daylight Agreement, the Company assumes responsibility for the commercialization and sale of Culpeo, in addition to the ability to incorporate the intellectual property into optimized products over the term of the Daylight Agreement. Daylight will continue to sell the products in the specified fields of Aerospace and Defense. Collaboration Agreements The Company licenses certain technologies that are, or may be, incorporated into its technology under several agreements and also has entered into several clinical research agreements that require the Company to fund certain research projects. Generally, the license agreements require the Company to pay annual maintenance fees and royalties on product sales once a product has been established using the technologies. Research and development expenses associated with license agreements were immaterial amounts for the years ended December 31, 2022, 2021 and 2020. In June 2018, the Company secured an agreement with Navigo Proteins GmbH (“Navigo”) for the exclusive co-development of multiple affinity ligands for which Repligen holds commercialization rights. The Company is manufacturing and supplying the first of these ligands, NGL-Impact ® , exclusively to Purolite, an Ecolab Inc. company ("Purolite"), who is pairing the Company’s high-performance ligand with Purolite’s agarose jetting base bead technology used in their Jetted A50 Protein A resin product. The Company also signed a long-term supply agreement with Purolite for NGL-Impact and other potential additional affinity ligands that may advance from the Company’s Navigo collaboration. In September 2020, the Company and Navigo successfully completed co-development of an affinity ligand targeting the SARS-CoV-2 spike protein, to be utilized in the purification of vaccines for the COVID-19 pandemic, including emerging variants of the SARS-CoV-2 coronavirus. The Company has proceeded with scaling up and manufacturing this ligand and the development and validation of the related affinity chromatography resin, which is marketed by the Company. In September 2021, the Company and Navigo successfully completed co-development of a novel affinity ligand that addresses aggregation issues associated with pH sensitive antibodies and Fc-fusion proteins. The Company is manufacturing and supplying this ligand, NGL-Impact ® HipH, to Purolite. The Navigo and Purolite agreements are supportive of the Company’s strategy to secure and reinforce the Company’s proteins business. The Company made payments to Navigo of $ 2.6 million, $ 2.3 million and $ 0.9 million in the years ended December 31, 2022, 2021 and 2020, respectively, in connection with this program, which are recorded to research and development expenses in the Company’s consolidated statements of comprehensive income. Purchase Orders, Supply Agreements and Other Contractual Obligations In the normal course of business, the Company has entered into purchase orders and other agreements with manufacturers, distributors and others. Outstanding obligations at December 31, 2022 of $ 72.1 million are expected to be completed within one year. Legal Proceedings From time to time, in the normal course of its operations, the Company is subject to litigation matters and claims relating to employee relations, business practices and patent infringement. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict, and the Company’s view of these matters may change in the future as the litigation and events related thereto unfold. The Company expenses legal fees as incurred. The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. An unfavorable outcome to any legal matter, if material, could have an adverse effect on the Company’s operations or its financial results. 106 13. Convertible Senior Notes The carrying value of the Company’s convertible senior notes is as follows: December 31, 2022 December 31, 2021 (Amounts in thousands) 0.375% Convertible Senior Notes due 2024: Principal amount $ 287,470 $ 287,489 Unamortized debt discount — ( 28,220 ) Unamortized debt issuance costs ( 2,855 ) ( 4,011 ) Net carrying amount $ 284,615 $ 255,258 0.375% Convertible Senior Notes due 2024 On July 19, 2019, the Company issued $ 287.5 million aggregate principal amount of the 2019 Notes, which includes the underwriters’ exercise in full of an option to purchase an additional $ 37.5 million aggregate principal amount of 2019 Notes (the “Notes Offering”). The net proceeds of the Notes Offering, after deducting underwriting discounts and commissions and other related offering expenses payable by the Company, were approximately $ 278.5 million. The 2019 Notes are senior, unsecured obligations of the Company, and bear interest at a rate of 0.375 % per year. Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020 . The 2019 Notes will mature on July 15, 2024 , unless earlier repurchased or converted in accordance with their terms. The initial conversion rate for the 2019 Notes is 8.6749 shares of the Company’s common stock per $ 1,000 principal amount of 2019 Notes (which is equivalent to an initial conversion price of approximately $ 115.28 per share). Prior to the close of business on the business day immediately preceding April 15, 2024, the 2019 Notes will be convertible at the option of the holders of 2019 Notes only upon the satisfaction of specified conditions and during certain periods. Thereafter until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2019 Notes will be convertible at the options of the holders of 2019 Notes at any time regardless of these conditions. Conversion of the 2019 Notes will be settled in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. The 2019 Notes are not redeemable by the Company prior to maturity. Holders of 2019 Notes may require the Company to repurchase their 2019 Notes upon the occurrence of a fundamental change prior to maturity at a repurchase price equal to 100 % of the principal amount thereof, plus accrued and unpaid interest to, but excluding, the date of repurchase. In connection with certain corporate events, the Company will, under certain circumstances, increase the conversion rate for holders of 2019 Notes who elect to convert their 2019 Notes in connection with such corporate events. During the fourth quarter of 2022 , the closing price of the Company’s common stock exceeded 130 % of the conversion price of the 2019 Notes for more than 20 trading days of the last 30 consecutive trading days of the quarter. As a result, the 2019 Notes are convertible at the option of the holders of the 2019 Notes during the first quarter of 2023, the quarter immediately following the quarter when the conditions are met, as stated in the terms of the 2019 Notes. Expecting to continue meeting these terms, the Company will continue to classify the carrying value of the 2019 Notes as a current liability on the Company’s consolidated balance sheet as of December 31, 2022 . These conditions have been met since the third quarter of 2020. As a result, as of the date of this filing, the Company has received requests to convert $ 30,000 aggregate principal amount of the 2019 Notes all of which have settled. The conversions resulted in the issuance of a nominal number of shares of the Company’s common stock to the note holders. Prior to the adoption of ASU 2020-06, the Company accounted for the 2019 Notes as a liability and equity component where the carrying value of the liability component was valued based on a similar debt instrument. In accounting for the issuance of the 2019 Notes, the Company separated the 2019 Notes into liability and equity components. The carrying value of the liability component was calculated as the present value of its cash flows using a discount rate of 4.5 % based on comparative convertible transactions for similar companies. The carrying value of the equity component representing the conversion option was 107 determined by deducting the fair value of the liability component from the par value of the 2019 Notes as a whole. The excess of the principal amount of the liability component over its carrying value amount, referred to as the debt discount, was amortized to interest expense on our consolidated statements of comprehensive income over the five-year term of the 2019 Notes. The equity component was not re-measured as long as it continued to meet the conditions for equity classification. The equity component related to the 2019 Notes recorded at issuance was $ 52.1 million, which was recorded in additional paid-in capital on the Company's consolidated balance sheets. In accounting for the transaction costs related to the issuance of the 2019 Notes, the Company allocated the total costs incurred to the liability and equity components of the 2019 Notes using the same proportions as the initial carrying value of the 2019 Notes. Transaction costs related to the liability component were $ 7.4 million and are amortized to interest expense using the effective interest method over the five-year term of the 2019 Notes. Transaction costs attributable to the equity component were $ 1.6 million and are netted with the equity component of the 2019 Notes in stockholders' equity of the Company's consolidated balance sheets. Additionally, the Company recorded a net deferred tax liability of $ 11.4 million. Effective January 1, 2022, the Company adopted ASU 2020-06. After adoption, the Company now accounts for the 2019 Notes as a single liability measured at amortized cost. As the equity component is no longer required to be split into a separate component, the Company recorded a net adjustment for the initial $ 50.4 million that was allocated to additional paid-in capital and $ 22.9 million of life-to-date interest expense recorded as amortization of debt discount. Additionally, the net deferred tax liability recorded for the 2019 Notes was reversed. The principal amount of the liability over its carrying amount is amortized to interest expense over the five-year term of the 2019 Notes. Since the 2019 Notes are classified as a single liability, there is no debt discount required to be amortized in 2022. Interest expense recognized on the 2019 Notes in 2022 was $ 1.1 million and $ 1.8 mill ion for the contractual coupon interest and the amortization of the debt issuance costs, respectively. The effective interest rate on the 2019 Notes is 1.01 %, which included the interest on the 2019 Notes, amortization of the debt discount and debt issuance costs. As of December 31, 2022, the carrying value of the 2019 Notes was $ 284.6 million and the fair value of the principal was $ 452.0 million. The fair value of the 2019 Notes was determined based on the most recent trade activity of the 2019 Notes as of December 31, 2022. The 2019 Notes agreement contains customary terms and events of default. If an event of default (other than certain events of bankruptcy, insolvency or reorganization involving the Company) occurs and is continuing, the holders of at least 25 % in aggregate principal amount of the outstanding 2019 Notes may declare 100 % of the principal of, and any accrued and unpaid interest on, all of the 2019 Notes to be due and payable. Upon the occurrence of certain events of bankruptcy, insolvency or reorganization involving the Company, 100 % of the principal of and accrued and unpaid interest, if any, on all of the 2019 Notes will become due and payable automatically. Notwithstanding the foregoing, the 2019 Notes provide that, to the extent the Company elects and for up to 270 days, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants consist exclusively of the right to receive additional interest on the 2019 Notes. The Company is not aware of any events of default, current events or market conditions that would allow holders to call or convert the 2019 Notes as of December 31, 2022 . 14. Accumulated Other Comprehensive Income (Loss) Changes in accumulated other comprehensive income (loss) consisted of the following for the years ended December 31, 2022 and 2021 (amounts in thousands): Foreign Currency Translation Adjustment Balance at December 31, 2020 $ 2,085 Other comprehensive loss ( 18,971 ) Balance at December 31, 2021 ( 16,886 ) Other comprehensive loss ( 17,508 ) Balance at December 31, 2022 $ ( 34,394 ) 108 15. Employee Benefit Plans In the United States, the Repligen Corporation 401(k) Savings and Retirement Plan (the “401(k) Plan”) is a qualified defined contribution plan in accordance with Section 401(k) of the Internal Revenue Code. All U.S. employees over the age of 21 are eligible to make pre-tax contributions up to a specified percentage of their compensation. Under the 401(k) Plan, the Company may, but is not obligated to match a portion of the employees’ contributions up to a defined maximum. The match is calculated on a calendar year basis. The Company matched $ 2.7 million, $ 1.8 million and $ 1.4 million in the years ended December 31, 2022, 2021 and 2020, respectively. In Sweden, the Company contributes to a government-mandated occupational pension plan that is a qualified defined contribution plan. All employees in Sweden are eligible for this pension plan. The Company pays premiums to a third-party occupational pension specialist who administers the pension plan. These premiums are based on various factors including each employee’s age, salary, employment history and selected benefits in the pension plan. When an employee terminates or retires, these premium payments cease for that employee and the Company has no further pension-related obligations for that employee. The Company contributed $ 1.1 million, $ 1.0 million and $ 0.6 million, respectively to the defined contribution plan for the years ended December 31, 2022, 2021 and 2020 . 16. Related Party Transactions Certain facilities leased by Spectrum are owned by the Roy Eddleman Living Trust (the "Trust"). As of December 31, 2022 , the Trust owned greater than 5 % of the Company's outstanding shares. Therefore, the Company considers the Trust to be a related party. The lease amounts paid to the Trust prior to the public offering were negotiated in connection with the acquisition of Spectrum. The Company incurred rent expense related to these leases totaling $ 0.7 million for the years ended December 31, 2022, 2021 and 2020 . 109